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Tuberculosis (TB) is an infectious disease caused by the organism Mycobacterium tuberculosis 
(MTB). Improved sanitation and successful chemotherapy have largely eliminated TB in 
industrialized countries, but it remains a serious threat to lower socio-economic classes, the 
immunocompromised population, and developing countries where industrialization is just taking 
hold. Although two new drugs have surfaced in the last decade, they are largely reserved for 
compassionate cases because of the severity of their side effects. The first-line TB treatment 
prescribed by the World Health Organization and the Center for Disease Control and Prevention 
remains the comparatively small number of drugs synthesized or isolated in the 1950’s and 
1960’s. These drugs, while currently effective, can cause adverse side effects such as liver 
toxicity. Additionally, the emergence of strains of drug-resistant TB threatens to completely 
undermine existing treatment regimens and enable TB to reach a level of prevalence not 
experienced for the past century. 
In the past decade, studies have suggested intriguing antitubercular possibilities offered 
by applying modern methods to a very early class of drugs: the sulfa drugs. Sulfa drugs work by 
mimicking the natural molecule para-aminobenzoic acid, inhibiting dihydropteroate synthase 
(DHPS) and resulting in cell death. Arylamine N-acetyltransferases (NATs) de-activate sulfa 
drugs inside the body by catalyzing the transfer of an acetyl group onto position N4 of the sulfa 
molecule. NATs also appear in M. tuberculosis, where they act as a defense mechanism for MTB 
against chemotherapy. 
 My work in the Hearn lab has been guided by recent crystallographic images of the 
DHPS binding pocket and the deactivating mechanism of NATs, as well as by previous studies 
in our lab that demonstrated that acylation can improve activity and bioavailability while 
	 5 
reducing toxicity. Our work began with the development of a reliable protocol to prepare the 
acetylated NAT metabolites. We then explored a number of different procedures for increasing 
acyl chain length at N4, focusing on derivatives of sulfamethazine; and then continued to 
selective di-acylation at both N4 and N1, varying both chain length and steric bulk for a number 
of different sulfa drug scaffolds. Several of our acylated sulfa derivatives possess improved 
biological and anti-tubercular properties over their parent drugs. Moreover, the compounds serve 
as probes of the structural factors influencing biological activity such as fit within DHPS, 





TUBERCULOSIS IN HISTORY: PHTHISIS AND CONSUMPTION 
	
Tuberculosis is an infectious disease caused by the organism Mycobacterium tuberculosis. It 
usually affects the lungs, but can also spread to other areas of the body such as the skin, bones or 
kidneys. The characteristic symptoms of pulmonary tuberculosis are chest pain, fatigue, 
chills/fever, night sweats, and a persistent cough that often includes expectorating blood or 
sputum.1 Biological research estimates that the modern strain of M. tuberculosis (MTB) surfaced 
approximately 20,000 years ago. The disease recurs frequently throughout history: archaeologists 
have found skeletal evidence of tuberculosis in 5,000-year-old Egyptian mummies, and ancient 
Greek philosophers and doctors wrote at great length of tuberculosis-like symptoms, possible 
causes, and suggested treatments. In the Middle Ages, the touch of a member of the royal family 
was thought to cure scrofula, the swollen lymph nodes that were often a sign of a tuberculosis 
infection.2 The prevalence of tuberculosis waxed and waned throughout the centuries. Though 
painful, debilitating, and almost always fatal by the time outward symptoms manifested, 
tuberculosis did not reach the peak of its reign as a terrifying plague until the nineteenth century, 
when the rise of industrialization created the perfect conditions for infection to flourish.3 
 The Industrial Revolution, which swept across Europe and the United States at the end of 
the 18th century, shifted the population from small farming communities to burgeoning urban 
environments. In that era, cities grew far too rapidly to maintain any kind of reasonable 
sanitation, and the idea that disease was contagious was mostly dismissed by medical 
practitioners of the time. Laborers were crammed together at work and at home in buildings that 
were poorly ventilated, filthy and overcrowded. With such exposure to the exhalations and 
bodily fluids of others, contagions of all kinds ran rampant. Today we understand that physical 
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and psychological stress can increase susceptibility to sickness, and there was a high quotient of 
misery in the new industrial lifestyle. Dubos writes about the “ubiquity of contagion” in the 
Industrial Era, adding that the higher social classes were by no means immune: “Physiological 
misery and crowding permitted the explosive spread of the disease among the labor classes, and 
from this huge focus the infection spread through society by means of countless unavoidable 
contacts.”3  
 Terrorized by the omnipresence of the illness and impressed by its lethality, society 
christened tuberculosis with several euphemisms, including “the Captain of All the Men of 
Death” and the “White Plague.”3 While medical science had made great strides since the 
Renaissance, tuberculosis was still poorly understood. Due to its varying presentations in 
different areas of the body, tuberculosis was frequently classified as many different diseases. In 
fact, as physicians grew more adept at distinguishing between different symptoms and 
classifying them accordingly, the single disease we would now identify as tuberculosis acquired 
many different diagnostic profiles.3 
Unlike a straightforward cold or influenza, the contagious nature of tuberculosis was 
difficult to discern because enormous swaths of the population were likely infected with the 
latent form of the disease. Dubos asserts “[i]t is certain that during the eighteenth and nineteenth 
centuries all dwellers in large cities of Europe became infected at an early age and remained in 
contact with heavily contaminated objects, sputum, food and dust throughout their life.”3 As a 
result, it was not a question of whether any given person was infected but who manifested the 
symptoms of an active infection, and how quickly and severely the disease progressed. Although 
the idea that tuberculosis was contagious had been proposed by an Italian scientist named 
Hyeronymus Fracastorius in 1596, and the idea briefly held sway in Southern Europe, it was by 
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the nineteenth century rejected by most physicians, especially in the northern parts of Europe. 
Instead, physicians believed that if a patient developed tuberculosis – or pulmonary phthisis, as it 
was called in its most familiar form – it was due to an inherent, constitutional susceptibility.3 The 
putative hereditary weakness frequently presented itself in one’s early twenties, or after some 
traumatic event or stressor. Apparent evidence for this theory was provided by the many 
members of family lines who developed tuberculosis at around the same point in their lives, 
often wiping out entire households. Due to tuberculosis’ long incubation period before becoming 
active and causing symptoms, the alternate explanation of a single source of infection or indeed 
an entire house permeated with the bacteria could not be conceptualized for many more years. 
For example, the tragic demise of the six siblings of the Brönte family and later their father, 
almost all from clear symptoms of tuberculosis, was simply attributed to their hereditary profile 
and not the effects of being confined together to a tiny, damp and poorly ventilated house.3,4 
While the infectious aspect of tuberculosis was denied, physicians struggled to treat its 
devastating symptoms. By the time a patient started coughing up blood, often the first 
recognizable sign of pulmonary infection, tuberculosis had already wreaked its destruction in the 
body and the patient faced a painful march toward death. With no coherent idea of the progress 
of tuberculosis inside the body, the prescribed treatment for symptoms varied wildly from 
physician to physician and from trend to trend. Common features included protection from fresh 
air by sealing the windows of the sickroom, an aggressive starvation diet to deprive the disease – 
and, by unfortunate side effect, the patient – of nutrients, and travel to milder climates for the 
calming and healing effects of balmy weather. Later in the nineteenth century, physicians 
prescribed horseback riding or other fresh-air exercise, high-fat diets, and total rest as treatment 
protocols.3  As medical science progressed and the value of rest for damaged lungs became 
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clearer, the concept was taken to the extreme – beginning in 1882 and continuing for about 
twenty-five years, the preferred technique for slowing the progress of tuberculosis was inducing 
pulmonary collapse through crude surgery.5 
These treatments were nominally informed by advances in medical knowledge regarding 
the various manifestations of tuberculosis and its pathogenesis. Gaspard Bayle and his student 
René Laënnec contributed to the existing repository of information about disease by performing 
hundreds of dissections on corpses with pulmonary phthisis. They meticulously detailed the 
types and consistencies of tubercles, the spherical nodules that form in the lungs around sites of 
tuberculosis infection. Before his own early death of tuberculosis, Laënnec proposed his inspired 
unified theory of tuberculosis.3 In 1804, decades before it would be accepted by the medical 
world at large, Laënnec outlined how infiltration, tubercles and open cavity ulcers were 
consecutive stages of a single illness. With no knowledge of germ theory, he nonetheless 
suggested that many diseases of the skin, lungs and other body parts which we would today 
recognize as caused by MTB were in fact multiple forms of one causative agent.3 In the study of 
his newly defined disease, Laënnec invented and promoted the use of the stethoscope, allowing a 
previously unparalleled level of auditory insight into a patient’s body cavities, especially the 
lungs. He was partially inspired by another advance made at the turn of the nineteenth century: 
Jean-Nicolas Corvisart’s resurrection of a technique written about by Josef Auenbrugger thirty 
years earlier, in which the quantity of fluid in a patient’s lungs could be determined by rapping 
on their sternum.3 This technique, called percussion, and the use of the stethoscope, called 
mediate auscultation, became the primary diagnostic tools for a physician to identify tuberculosis 
before its outward symptoms manifested, and remained crucial to the field for over a century. 
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Although tuberculosis was pervasive and incurable except by luck and happy accident, it 
nevertheless came to symbolize a certain brand of sickly beauty that became emblematic of the 
Romantic Era’s art and literature. Protagonists in the Victorian novel and in the plethora of 
operas being composed at the time frequently suffered from tuberculosis – notable examples 
include La Bohème and La Traviata.6 Poets idolized the short and painful lives of tuberculosis 
patients, incorporating the concept into the imagery and ideals expressed in their poetry. The pale 
and languid consumptive, with a feverish pallor and emaciated limbs, appeared frequently in 
Romantic paintings as an ideal of feminine beauty.7 Lord Byron once joked, “I should like to die 
of consumption… because the ladies would all say, ‘Look at that poor Byron – how interesting 
he looks in dying.’” Alexandre Dumas commented that it was “the fashion to suffer from the 
lungs; everybody was consumptive, poets especially; it was good form to spit blood after any 
emotion that was at all sensational, and to die before reaching the age of thirty.”3 
As these assertions suggest, there was also an association between tuberculosis and 
artistic genius, a view that was compounded by the suffering of an extraordinary number of 
poets, writers and other luminaries of the time. Since tuberculosis was viewed as a hereditary 
defect, it followed that it could be especially prevalent in those gifted with extraordinary mental 
faculties. The early death of John Keats at the age of 26 was heavily romanticized by PB Shelley 
and his contemporaries; the suffering of the self and of others was synonymous with mental 
exertion and creation. The Brönte family is the quintessential example, but tuberculosis also 




THE BIRTH OF BACTERIOLOGY 
	
In the last two decades of the nineteenth century, a number of extraordinary discoveries 
revolutionized the field of medicine. Primary among them was the bacteriological work 
performed by Robert Koch, a German scientist. Through the development of new microscopy 
and inoculation techniques, he was able to isolate the bacteria responsible for a number of major 
diseases, including tuberculosis.8 In 1880, Koch published and presented his work demonstrating 
the existence of M. tuberculosis, along with a list of four postulates regarding bacterial science 
that still underpin the field today.9 With Koch’s definitive evidence of his discovery, different 
manifestations of tuberculosis could be traced back to the same bacteria, and germ theory entered 
the medical lexicon as a substantive concept. 
Despite this stunning achievement, for a few decades the discovery had surprisingly little 
impact on the practical applications of identifying and treating tuberculosis. The omnipresence of 
the disease presented a great difficulty – although tuberculosis had been proven to be quite 
infectious, a strategy of isolation and quarantine was functionally useless when most of the 
population already carried the bacteria in some form.3 Unfortunately, Koch’s stellar reputation 
was later tarnished when he announced his development of tuberculin, a non-infectious 
substance which he had isolated and believed to be an effective vaccine for increasing resistance 
to the destructive form of the disease. While tuberculin did have an application under a very 
narrow set of circumstances, in most of the population it caused a severe allergic reaction in the 
body, and in some cases actually worsened a patient’s tuberculosis.3 Despite this failure, a 
modified form of tuberculin is still used today as a simple test for the presence of latent 
tuberculosis. In a method developed by Clemens von Pirquet in 1907, tuberculin is injected 
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intravenously under the skin; the area is monitored for redness and swelling, which together 
indicate the presence of the tuberculosis bacteria.10 
In a curious blend of the previous century’s treatment protocols and a new understanding 
of tuberculosis as an infectious disease, a movement swept across America and parts of Europe 
in the early 1900’s to open tuberculosis sanatoria.  A tuberculosis sanatorium was designed as a 
restful haven for patients, simultaneously isolating them from the general population and 
allowing them the fresh air and mild climate that many believed were beneficial to the healing 
process. They also created an environment where tuberculosis patients had constant access to 
knowledgeable and specific medical care. While they did unquestionably ease a patient’s 
suffering during the lengthy progression of the disease, they were not a miracle cure and 
ultimately did not meaningfully affect the overall fatality rate for tuberculosis.3 
 As a more precise understanding of tuberculosis filtered into the public consciousness 
and the social conscience corrected itself from the industrial age, humanitarians pioneering 
improvements in sanitation and working conditions found their goals aligned with those seeking 
to understand and prevent tuberculosis epidemics. As a result, private collectives in America 
launched one of the first real public health initiatives in history, hoping to prevent the spread of 
and increase diagnosis rates for tuberculosis. In 1904, the National Association for the Study and 
Prevention of Tuberculosis was founded with a mission statement to “embrace not only the 
scientific study of the disease of tuberculosis, but a study of all its relations to man, social and 
economic, and all measures for its prevention, eradication and cure.”3 This movement was the 
first appearance of the idea that the public as a whole had a responsibility to enact conditions that 
promoted the safety and well-being of its members, and that a contagious individual had the 
moral obligation to seek treatment and attempt to control the spread of their illness. 
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 Though rates of tuberculosis had been in decline over the previous century, they peaked 
again when the World Wars raised the collective levels of stress and violence. During this time, 
X-rays became a valuable way to examine body cavities without invasive surgery, allowing 
identification of tuberculous patients before they started exhibiting symptoms.2 Combined with 
auscultation, X-rays became the primary method of diagnosis. In the US in the 1940’s, X-rays 
were used to examine the lungs of potential soldiers who wished to enlist to fight in World War 




Once the bacteriological origin of tuberculosis had been discovered, rapid progress towards 
characterizing and treating the disease became possible, uniting scientific disciplines as diverse 
as biology, chemistry, and the newborn field of bacteriology.  Among the many advances in the 
1930’s and 1940’s were the discovery of the highly lipoid nature of the cell wall of M. 
tuberculosis and the first scientifically rigorous attempts at tuberculosis chemotherapy.3 This 
progress laid the groundwork for a modern understanding of its pathogenesis and treatment. 
Today, we know that tuberculosis infection begins with the introduction of its 
characteristic bacteria, usually through the inhalation of contaminated sputum.12 Unlike many 
bacteria-borne illnesses, however, tuberculosis is often neutralized rapidly by the immune 
system. Macrophages cordon off pockets of the bacteria, forming thick-walled nodules that 
prevent the infection from spreading but also keep the tuberculosis bacteria alive within the 
cellular environment.12 These nodules range in size from microscopic to visible to the naked eye, 
and it is the advanced form of these nodules that earlier practitioners of medicine identified as 
tubercles.3 A healthy body can frequently exist in this stalemate for years or even decades, until a 
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trauma or other sudden change in the immune environment precipitates the rupture of these 
nodules and the release of their contents into the bloodstream.13,14 This long period of inactive 
incubation is one of the reasons tuberculosis has historically been more difficult than other 
bacterial infections to identify and treat. Once this “sneak attack” floods the body with the 
necrotic contents of the tubercles, the bacteria have multiplied to a point where containment is 
impossible.14 The patient enters the active stage of tuberculosis and begins manifesting 
symptoms as the lungs and/or other infected tissues are destroyed. Left untreated, tuberculosis is 
fatal in 70% of cases.12 
 Another notable feature of tuberculosis is the natural defense characteristics its bacteria 
employ. The Mycobacterium genus possesses an exceptionally thick and waxy cell wall, which 
surrounds the bacterium and protects it from both the body’s immune system and the destructive 
effects of traditional antibiotics.3,12 Its inactive period may also be related to its extremely slow 
cell growth rate, which is distinctive to MTB.15 Its unique structure and infectious process have 





Chemotherapy was precipitated by the discovery of penicillin and the sulfa class of drugs in 
1928 and 1932, respectively. Unfortunately, these otherwise versatile drugs were not effective 
against tuberculosis.16 The unique difficulties presented by MTB required several more decades 
of experimentation before the first effective anti-tubercular drugs were developed. The initial 
foray into the field yielded thioacetazone, otherwise known as conteben, which was prepared by 
German scientist Gerhard Domagk in 1945. Around the same time, Jorgen Lehmann first 
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reported the synthesis of para-aminosalicylic acid, or PAS.17,18 Though results for the two drugs 
were initially promising, they eventually proved to be bacteriostatic, preventing the 
multiplication of MTB without killing it (Fig. 1). In 1944, Allied scientists demonstrated the 
efficacy of streptomycin against MTB. While the drug caused a few miraculous recoveries, it 
also proved to have serious side effects. In addition, when it was administered as the only 
treatment for tuberculosis, bacterial resistance to the drug would quickly develop.3 
 
Figure 1. Chemical structure of thioacetazone and para-aminosalycylic acid. 
Both discovered 1945 and bacteriostatic. 
 
 The turning point in anti-tubercular drug design occurred in 1952, when multiple 
laboratories simultaneously synthesized isonicotinylhydrazide, commonly known as isoniazid or 
INH.17 In contrast to previous attempts at chemotherapy, isoniazid was safe and effective, and it 
became the first reliable cure for tuberculosis. With its widespread use, sanatoria became 
obsolete and patients were able to return home to receive treatment. Further experimentation 
demonstrated the optimal treatment of the time was “triple therapy,” a combination of INH, PAS 
















Figure 2. Left: Chemical structure of INH, PAS and streptomycin, dispensed 
in combination as “triple therapy.” Right: Chemical structures 
for Rifampin and ethambutol, dispensed in combination after discovery with INH. 
  
 In 1957, a laboratory in Italy isolated the rifamycin class of drugs from cultures of 
Streptomyces mediterranei; further optimization of these drugs provided Rifampin.16 Along with 
the 1961 discovery of ethambutol, Rifampin became an excellent replacement for PAS, and the 
new standard became Rifampin, isoniazid and ethambutol (Fig. 2).17  This combination 
shortened treatment to six months and also proved to be effective against strains of the bacteria 
that had become resistant to isoniazid and streptomycin. Pyrazinamide had been explored 
previously and abandoned due to side effects but at a lower dose was found to be another good 
option for combination therapy.17 
 With the advent of combination therapy, the incidence of tuberculosis fell rapidly in 
developed countries throughout the 1960’s, and research into new drugs to treat the disease was 
deprioritized as other health crises took precedence. However, in the late 1980’s there was an 





















tuberculosis, abbreviated to MDR-TB.17,19 While improved sanitation and aggressive 
chemotherapy treatment have largely eliminated tuberculosis in the middle and upper classes of 
industrialized countries, it remains a serious threat to lower socio-economic classes and the 
immunocompromised population.20 
With the rise of HIV/AIDS, tuberculosis has resurfaced as the lethal plague that it once 
was; tuberculosis is the leading cause of death in patients with AIDS.17 In addition, the same 
conditions of poverty and neglect that once characterized the industrializing cities of America 
and Europe are now prevalent in other countries embracing a modern level of urban 
development. Tuberculosis has increased proportionally in response in those cities, the same way 
it once plagued cities like London, Paris and New York.20 In its yearly Global Tuberculosis 
Report, the World Health Organization (WHO) shares a few chilling statistics:  
In 2017, TB caused an estimated 1.3 million deaths (range, 1.2–1.4 million) 
among HIV-negative people and there were an additional 300 000 deaths from TB 
(range, 266 000–335 000) among HIV-positive people…. Globally, the best 
estimate is that 10.0 million people (range, 9.0–11.1 million) developed TB 
disease in 2017: 5.8 million men, 3.2 million women and 1.0 million children.20 
 
 As the focus of wealthier countries has shifted to other illnesses, the development of anti-
tuberculosis drugs has slowed to a trickle. The first-line combination therapy currently 
prescribed by the WHO and the Center for Disease Control and Prevention (CDC) remains the 
comparatively small number of drugs synthesized or isolated in the 1950’s and 1960’s.20,21 This 
treatment is not without substantial flaws. Tuberculosis’ ability to persist for long periods of time 
inside the body requires a correspondingly lengthy treatment regimen; while a typical course of 
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antibiotics for another bacterial infection ranges typically ranges between ten days and four 
weeks, the prescribed treatment time for tuberculosis is six months at a minimum. This leads to 
poor patient compliance in finishing the treatment, especially because bacteria can persist long 
after the symptoms have subsided.22 Additionally, the current drugs prescribed can cause adverse 
side effects, including liver toxicity.23 Lastly and most compellingly, the emergence of 
multidrug-resistant tuberculosis, extensively drug-resistant (XDR-TB), and total drug-resistant 
tuberculosis (TDR-TB) threatens to completely undermine current treatment regimens and 






It is against this alarming backdrop that the pressure increases to develop new forms of drugs to 
combat tuberculosis. The advent of computational modeling combined with sensitive X-ray 
crystallography techniques has allowed the characterization of the processes through which 
bacteria develop resistance to specific types of anti-tubercular drugs. Guided by this exploration 
process, we can develop new chemotherapy agents specifically designed to counter those 
resistance mechanisms, with increased activity against TB, and able to endure the attempts of 
bacterial evolution to deactivate them. As strains of TB resistant to first-line treatment become 
more prevalent, a few studies suggest the intriguing possibilities offered by applying modern 




Sulfa drugs were some of the very first antibiotic agents ever discovered and remain a 
cornerstone of medical science. Also called sulfonamides, they are characterized by this 
eponymous group, which consists of a sulfonyl singly bonded to an amine. The sulfonamide is 
positioned adjacent to a phenyl ring, as seen in sulfanilamide, one of the simplest sulfa drugs 
(Fig. 3). 
Figure 3. Left: general structure of a sulfa drug, with sulfonamide shown in blue. Right: 














Sulfanilamide was the progenitor of the rest of the class, discovered by German scientist 
Gerhard Domagk in 1932 as part of a foray into the antibacterial properties of chemicals in the 
dye industry. Domagk won the Nobel Prize in 1939 for this discovery, an achievement which the 
Nazi Party recognized by arresting and jailing him. The red dye he had singled out was called 
“Prontosil,” and it was soon marketed by Bayer as the first broadly applicable antibacterial 
agent.24 Testing afterward in several other labs revealed Prontosil's activity within the body 
resulted from metabolism into the active component sulfanilamide, a molecule that was 
inexpensive, easily synthesized, and out of patent.25 A “sulfa craze” swept across the globe, 
lasting just over a decade, and sulfa derivatives were generated by the hundreds. Between 1935 
and 1945, organic chemists synthesized over 5,000 variations on the original sulfa structure, 
though “only about 20 were shown to have any medical value” (Fig. 4).26 The United States was 
by no means immune: in 1937 alone, the US exported 350,000 pounds of sulfa drugs!27 
 
Figure 4. The chemical structures of a few synthesized sulfa drugs with medicinal value.26  
 
The fervor cooled slightly as newer, more powerful antibacterial agents were discovered 
and popularized, among them the “wonder drug” penicillin. Sulfa drugs possessed a number of 
unfortunate properties, most notably their tendency to crystallize in the kidneys and urinary tract, 
causing excruciating pain.28 Moreover, sulfa drugs in monotherapy were not effective against 
tuberculosis, the scourge of the previous century and still a major health concern. Sulfa drugs 




















bacteria, they were unable to destroy bacteria extant in the body. Drugs were developed to treat 
specific illnesses, and a broadly applicable antibacterial agent lost some appeal.  Additionally, 
resistance to the sulfa drugs materialized, making treatment more difficult. The pharmaceutical 
field moved on, and by the end of the 1950's the drugs that originated modern chemotherapy had 
been largely supplanted.29 
It was not until the twenty-first century that a handful of observations rekindled interest 
in the sulfa drugs. When combined with trimethoprim, they showed unexpected efficacy against 
tuberculosis, offering a new avenue to combat strains that had developed resistance to more 
traditional chemotherapy. A pioneering paper in this area was published in 2009 by Pierre 
Forgacs and colleagues, in Antimicrobial Agents and Chemotherapy. The paper details the case 
study of an immunocompromised patient admitted to the Lahey Clinic Medical Center, who was 
initially believed to be infected with nocardiosis but was later diagnosed with tuberculosis. 
Following procedure when doctors suspected the former infection, he received an intravenous 
combination of trimethoprim (TMP) and sulfamethoxazole (SMX) for two and a half weeks. In 
that time, before tuberculosis was detected and the patient was switched to traditional TB 
chemotherapy, the patient defervesced and showed “soft” symptoms of improvement; the paper 
outlines how this “was unlikely to be due to factors other than a response of his tuberculosis 
infection to [TMP-SMX] therapy.”29 
This was a very surprising result – since the 1950’s tuberculosis had been thought to be 
unaffected by TMP-SMX, and indeed by sulfa drugs as a class. Forgacs and colleagues collected 
the strain of MTB that had been isolated from the patient, as well as 44 other isolates. Using 
guidelines modified from the Clinical & Laboratory Standards guidelines for “related 
organisms,” they tested the isolates’ susceptibility to TMP-SMX. Results showed that “[f]or 43 
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of 44 isolates of M. tuberculosis, including 4 of 4 multidrug-resistant (MDR) isolates, there was 
at least an 80% inhibition of growth at a MIC of ≤1/19 µg/mL of TMP-SMX… For 36 of 44 
isolates (82%), there was at least a 99% inhibition by ≤2/38 µg/mL of TMP/SMX.”29 Since the 
scientific consensus on TMP-SMX combination therapy seemed to be incorrect, Forgacs and 
colleagues trawled through past literature to ascertain how the idea had come to be accepted as 
medical gospel. They found that very early literature on the sulfa drugs demonstrated they were 
weakly active against tuberculosis, in the sense that they worked to a small degree and no better 
antibacterial agents had yet been discovered. The authors narrowed down the source of the TMP-
SMX confusion to one study on one isolate of MTB, performed by Wellcome Laboratories in 
1968. The pivotal aspect is that this 1968 experiment was performed on an egg yolk medium, 
which today is not recommended for TMP-SMX testing because it may “produce false 
resistance.” The single test was by no means comprehensive, yet it resulted in the neglect of an 
entire class of drugs for decades. Forgacs and colleagues close this revolutionary paper by 
suggesting further research into TMP-SMX as a drug to treat MTB, including strains that have 
become resistant to first-line tuberculosis treatments.29 
In the five years that followed, several other laboratories followed up on this rediscovery. 
Leslie, Ong, and Sievers wrote eight months later to the same journal that had published 
Forgacs’ research, confirming the original results and expanding on them with twelve new in 
vitro studies. Leslie and colleagues suspected the sulfa moiety to be the source of the 
combination therapy’s effect, but Forgacs countered with a 1982 study that demonstrates 
trimethoprim increases the efficacy of sulfamethoxazole by two to four times in one-third of M. 
fortuitum isolates, a close relative of tuberculosis.30 The text of the 1982 study, however, 
concludes that M. fortuitum is largely resistant to TMP despite being affected by SMX. It also 
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notes “marked differences in susceptibility among the various species” of the Mycobacterium 
genus.31 At this point in time, the value of TMP in combination therapy had not been definitively 
ascertained. 
In 2014, Davies Forsman in Sweden continued the research into sulfa combination 
therapy, leading a team of researchers in a large-scale study of the efficacy of sulfamethoxazole 
against MDR- and XDR-TB. The new study cited a number of studies done in the intervening 
years identifying sulfamethoxazole as the active component of TMP-SMX therapy, and reported 
its efficacy in combination with trimethoprim. This portion of the study found “[n]o significant 
differences in the MIC distributions between MDR-TB, XDR-TB, or isolates with other 
resistance patterns…. All isolates had MICs of 38 mg/liter of SMX….” Referring both to their 
own results and a large number of other studies, Davies Forsman and colleagues conclude that 
TMP-SMX combination therapy is active against even highly drug-resistant strains of MTB, 
with the caveat that it is most effective when MTB bacteria are found extracellularly.32  
In a short correspondence with Clinical Infectious Diseases regarding a 2016 review, 
Didier Raoult concisely summarizes the struggles facing current research into tuberculosis 
chemotherapy. He mentions several “old” antibiotics, including sulfadiazine, and writes, “In 
practice, it is necessary to use the patrimony of old antimicrobial compounds, even in fields in 
which segregation has eventually led to the thinking that only specific drugs could be 
effective.”33 His commentary was received with traces of resentment by the original authors of 
the review, who penned a response arguing that Raoult’s “suggestion that [they] were advocating 
an abandonment of older antibiotics in order to use newer molecules is not accurate.” They also 
call for a “comprehensive approach to the development of new regimens,” the value of which 
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any scientist in or adjacent to the field of medicine can see.34 In order to make progress against 
such a dangerous disease, we must make use of the entire array of tools at our disposal. 
 
DHPS AND FOLATE SYNTHESIS 
	
A modern usage for drugs from a previous century requires a modern understanding of their 
mechanism. Sulfa drugs target the process by which bacteria synthesize folate products, which 
are essential for the “biosynthesis of a diverse range of cellular components.”35  
 
Folate Pathway 
Living cells require folate products in one form or another, and prokaryotic cells are no 
exception. While mammals obtain folate in their diet and utilize it through an active transport 
system, plants and microorganisms such as tuberculosis bacteria must synthesize it through their 
own biochemical pathways.35 This dichotomy offers an excellent opportunity for targeted drug 
action, as drugs inhibiting folate synthesis can prevent further bacterial growth without harming 
the human host.  
The step of interest for sulfa drug action is that of para-aminobenzoic acid, or pABA. 
pABA binds through condensation with 6-hydroxymethyl-7,8-dihydropterinpyrophosphate 
(DHPP), producing a covalently bonded single molecule of 7,8-dihydropteroate. This reaction 
occurs when both pABA and DHPP are bound to the catalytic enzyme dihydropteroate synthase, 
or DHPS.35 X-ray crystallography provides a closer look into the minutiae of this mechanism. 
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Figure 5. Reaction between DHPP and pABA catalyzed by DHPS. Figure 
from Lee et al. 2012.36 
 
Crystallographic analysis of the binding pocket of DHPS reveals two “flexible, 
organized” loops that interact with the key substrates. Three substrates coordinate in this area: 
DHPP, pABA, and an octahedrally coordinated Mg2+ ion. Loop 1 creates a lid over the active 
site to form a “restricted entrance” matching pABA’s precise shape, while loop 2 wraps around 
pABA, stabilizing it in the pocket. The reaction itself follows an SN1-like mechanism: 
pyrophosphate is removed from DHPP, a cationic resonance structure forms that is stabilized by 
the binding pocket as well as delocalization around the pterin ring, and then the amino nitrogen 





Since the Woods-Filde Theory of Competitive Inhibition was proposed in 1940, it has been 
understood that sulfa drugs mimic pABA in the folate pathway.28 The exact details, however, 
were not elucidated until much more recently. Using cutting-edge crystallography and 
computational tools, scientists Stephen White and colleagues have provided detailed pathways 
and structural illustrations of the individual steps involved in sulfa drugs' mechanism of action.  
Sulfa drugs inhibit the folate pathway by binding to dihydropteroate synthase (DHPS) in 
the place of its natural substrate pABA. The structural explanation for sulfa drugs’ mimicry of 
pABA in this process is abundantly clear from three-dimensional modeling. The figure below 
(Fig. 6) uses sulfamethoxazole as an example: the sulfa drug matches the structure of pABA 
nearly perfectly, with its sulfonamide acting as an isostere to pABA’s carboxylate region and a 
similar phenyl group interacting with the lipophilic loops nearby.36 
 
Figure 6. Left: Crystal structure of sulfamethoxazole bound in DHPS, from Lee et al. 2012.36 
Right: chemical structure of sulfamethoxazole, top, and pABA, bottom. 
 
Unfortunately, resistance to sulfa drugs can develop rapidly, and the flexible nature of 
pABA binding ensures the endogenous function of the enzyme can still be performed even when 











conformation, with the methoxazole ring (or other N1 substituent) sticking out of the pocket at 
the solvent front (Fig. 6). Mutations in DHPS that result in resistance to sulfa drugs occur near 
this protrusion, “relegating sulfonamide-based therapies to second- or third-line options.”36 
Because of this discrepancy between sulfa and pABA structure, any further extensions out of the 
binding pocket should be avoided. 
On the other hand, the DHPP (“pterin”) portion of the binding pocket is deeper in the 
DHPS protein, and structurally specific such that any mutations would also critically affect the 
function of the enzyme. These observations point to structural modification on the other side of 
the sulfa drug molecule, near the arylamine and away from the varying ring structure – a thiazole 
ring in the case of sulfathiazole, for example. Although the bulk of this crystallographic work 
was performed using DHPS enzymes from Bacillus anthracis and Yersinia pestis, it can 
nonetheless guide hypotheses for structural modifications to fight MTB. Further work in the 
White lab has already demonstrated this principle with the use of pterin-sulfa conjugates, 
discussed in more detail in the next section.37 
 
Drug Design 
Several small molecules have been designed to take advantage of the pterin binding site. Another 
option is “dual-site binders” that interact with both the pterin and pABA binding site while not 
extending too far out of the binding pocket.37 The concept of dual-site binders recurs throughout 
the literature; multiple authors muse on the value of “designing a molecule that is able to bridge 
between the two substrate sites.”35 However, much of the dual-site binder work occurred prior to 
the 2012 paper identifying the SN1-like mechanism of DHPS catalysis. As such, the molecular 
design relied on incorrect assumptions and the drugs were inactive.37 
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Stephen White and colleagues not only elucidated the DHPS catalysis mechanism but 
were also among the first to synthesize drugs that took advantage of this new information. In 
2016, the laboratory published a paper regarding pterin-sulfa conjugates as DHPS inhibitors.38 
Their novel synthetic methods yielded compounds that can engage both sulfa drugs' original 
binding site as a pABA mimic and the pterin binding site deeper in the cleft of DHPS. Assays 
demonstrate that these compounds have genuine antibacterial activity, inhibiting DHPS and 
acting as antagonists to the folate pathway, in addition to their ability to interfere by conjugating 
with DHPP to form “dead-end” products. While these compounds are around ten times less 
active than their parent sulfa drugs, they are excellent candidates for lead compounds. Their 
conjugation of the reactive arylamine may also offer a decrease in sulfonamide anaphylaxis, 





The primary metabolic pathway through which sulfa drugs are deactivated inside the body 
involves arylamine N-acetyltransferases, or NATs. NATs are responsible for catalyzing the 
transfer of an acetyl group from acetyl-Coenzyme A (AcCoA) onto the terminal amine of an 
arylamine substrate.39,40 They are found in many species, including humans and M. tuberculosis. 
Studies focusing on exclusively on a single species can resolve mysteries regarding the immune 
system and metabolism. In contrast, examining the polymorphisms – structural variants within 
different forms of the same enzyme – as they occur across multiple species can provide insight 
into the structure and function of the NAT enzyme class as a whole.40 
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Human NATs and TB-NATs 
NATs in MTB participate in the synthesis of the mycobacterial cell wall, which is exceptionally 
thick and tough and allows MTB to survive attack by the immune system. It may be possible to 
exploit NAT mutations in MTB that make the cell wall permeable to antibiotics that would 
usually have no effect. This could provide a potential method to treat drug-resistant tuberculosis 
in parts of the world where this mutation is found.40 Unfortunately, experiments regarding 
metabolism of drugs by TB-NATs are difficult; TB-NATs are notoriously intractable and 
unstable, and strict biological controls are required to study live tuberculosis bacteria.41 Several 
analogues of MTB are therefore employed, including M. marinum and the attenuated form of M. 
bovis known as Bacille Calmette-Guérin (BCG).39,40 NAT enzymes in MTB are identical to the 
enzymes in BCG, indicating efficacy studies against the latter bacteria should apply to MTB, at 
least as far as metabolism is concerned.  
Humans possess two isoenzymes of NATs, designated NAT1 and NAT2. The two human 
NAT enzymes (H-NATs) are 87% similar but act on different substrates. Human NAT1 has a 
wide selectivity profile which includes pABA and para-aminosalicylic acid; its endogenous 
purpose seems to be acetylating the folate derivative p-aminobenzoylglutamate. NAT2, found 
primarily at “traditional sites of drug metabolism” such as in the liver and gut, has a more 
selective profile that includes isoniazid and the sulfa drugs.39 
In drug design, we consider the action of both TB-NATs and H-NATs. Much of this 





Structural Elucidation through Polymorphisms 
The mechanism of action of NATs is a central question that must be answered to target these 
enzymes with small molecules. Crystal structure analysis of NAT enzymes across multiple 
species suggests action at all three domains of the enzyme, engaging in a “universal reaction 
mechanism” involving a catalytic triad that does not vary by species: a cysteine residue, a 
histidine residue, and an aspartic acid residue.39 The C-terminal region is partially responsible for 
the high specificity of these enzymes, as it is “involved in interactions with substrates in the 
active site cleft."40 
Kinetic studies on a variety of both prokaryotic and eukaryotic NATs have demonstrated 
that substrate specificity differs between species, implying that NATs may have different roles in 
different organisms.42 Although this diversity is intriguing, all studies to date have shown an 
identical mechanism for acetyl transfer. Early studies with bird NATs helped pave the way 
towards a complete mechanism; the work was culminated by Blanchard and colleagues, who 
“provide[d] a detailed understanding of the kinetic and chemical mechanism” of TB-NAT and 
illustrated their results with the figure below (Fig. 7).40,42 It is easy to see the catalytic triad 
interacting with AcCoA, stabilizing the acetyl group before transferring it to the amine of the 





Figure 7. Proposed mechanism for NAT-catalyzed acetyl transfer, from Blanchard et al.42 
 
 
After years of hypothesizing the differences between Human NAT1 and NAT2 based on 
less complicated species, a crystal structure was solved for both variants in high resolution, 
including NAT2 complexed with Coenzyme A. The human models are similar to their 
prokaryotic analogues in that the protein is divided into the traditional three domains, but include 
a 17-residue insertion that affects the structure of the C-terminus. As in previous studies, the 
catalytic triad that drives NAT activity is clearly composed of Cysteine-68, Histidine-107, and 
Aspartate-122, maintained in an identical position in each crystal structure by “a complex 
network of non-bonding, polar interactions.”43 
The endogenous role of Human NAT1 is to metabolize folate derivatives by transferring 
the acetyl group from AcCoA. However, an examination of the interaction of folate itself with 
Human NAT1 (and its mouse analogue) reveals an additional folate-dependent mechanism for 
hydrolysis of the AcCoA molecule without transferring the acetyl to an arylamine substrate. This 
reaction is proposed to also be endogenous.44 Structural analysis suggests a mechanism of action 
where folate binds to the catalytic active site and affects the conformation of the enzyme, 
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allowing water to enter the normally lipophilic binding pocket. This hydrolysis reaction in the 
presence of folate was not observed in Human NAT2 (nor its mouse analogue).44 
In examining substrate specificity, crystallography indicates that NAT2’s phenylalanine 
at position 93 creates a hydrophobic “lid” that critically affects its selectivity by altering the 
“interactions with the pocket surface at this position.” This Phe-93 ensures that sulfa drugs bind 
almost exclusively to NAT2, by conforming into a hinged structure around the sulfonyl group 
(Fig. 8). The authors of the paper also identified “key features” that can structurally affect some 
of the polymorphisms of NAT1 and NAT2 and cause “defective function,” which can lead to 
differences in speed and efficacy of drug metabolism.43  
 
Figure 8. Sulfamethazine in NAT2 binding pocket. Shown in stick-and-ball 
representation (left) and schematic representation (right). From Plotnikov et al. 2007.43 
 
 
Metabolism & Drug Design 
While NAT1 has a clear endogenous purpose related to the folate pathway, NAT2 is thus far 
only understood as a “drug metabolizing enzyme.” Some of the earliest NAT research 
demonstrated the existence of two distinct phenotypes of NAT2, a “fast” and a “slow” 
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acetylation type. The slow acetylation phenotype decreases metabolism of isoniazid and other 
arylamines, including sulfa drugs. While this increases exposure, it also increases risk of adverse 
reaction, hepatotoxicity and certain types of cancer. These concerns suggest treatment regimens 
guided by genetic testing of NAT2 to improve efficacy and control toxicity risk.40,45 
 Though the existence of this division in the population has been known for decades, 
modern kinetic analysis was required to shed some light on isoniazid and its interaction with 
NAT enzymes. For example, it has long been hypothesized that MTB's ability to develop 
resistance to isoniazid is related to over-expression of NATs. This theory was recently 
determined to be unlikely; while substituted arylamines in general are excellent substrates for 
TB-NATs, isoniazid is an “extremely poor” substrate relative to others in the class.42  
 As research into the metabolism and biological pathways of anti-tuberculosis drugs 
continues, we can use the last decade's elucidation of NAT polymorphisms to conceive of 
personalized chemotherapy adapted to suit a person's specific genetic makeup. In a 
representative study, Azuma and co-authors propose a “pharmacogenetically stratified” approach 
to tuberculosis treatment to reduce the frequency of INH-induced liver damage. Currently, there 
is a single recommended dose of isoniazid for all patients, which is “too high for slow acetylators 
and insufficient for rapid acetylators.”23 By genotyping patients before they begin treatment, 
physicians can determine if they fall into the slow acetylation or rapid acetylation category. In 
the trial of 172 Japanese patients, some patients were assigned to standard treatment without 
genotyping, while another group was sorted genetically according to their markers for speed of 
acetylation. All patients received the internationally recommended treatment for adult pulmonary 
tuberculosis, aside from the variable dosage of isoniazid: a low dosage for slow acetylators, a 
standard dosage for the control group and intermediate acetylators, and a high dosage for rapid 
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acetylators. The genetically stratified group experienced “much lower incidences of unfavorable 
events” such as liver damage or treatment failure, while maintaining – and in some cases 
improving – therapeutic efficacy across all groups. The authors posit “personalized medicine” of 
this kind to be “obviously safer and more efficacious,” and “expect it to become the standard of 
care.”23 While there is some delay required in order to genotype patients before beginning 
treatment, this is compelling evidence that attention should be paid to the role of NAT 
acetylation when considering drug dosage and metabolism. 
The Sim research group, which has conducted much of the pivotal research on NAT 
enzymes, recently applied these principles in their examination of piperidinol derivatives. Thhis 
class of compounds has been earmarked for further research due to its potential 
antimycobacterial properties and inhibition of NATs. Once synthesized or acquired, the 
derivatives were tested for their antimycobacterial activity against Mycobacterium marinum. 
These compounds inhibit NAT by a “prodrug-like mechanism” where the piperidinol is activated 
to a phenyl vinyl ketone (PVK); the PVK fragment then forms a covalently-bonded adduct with 
NAT’s active-site cysteine.41 Obviously, a complex understanding of NAT mechanism was 
necessary to explore this class of compounds. It is important to note that potency measures were 
carried out with MM-NAT, in place of TB-NAT. While results appear “comparable” for most 
compounds, there is some discrepancy. Crystal structures and computer modelling suggest the 
piperidinols bond to an area in the binding pocket that is significantly “more charged and polar” 
in MM-NAT.41 Lastly, a few more potential NAT inhibitors were suggested through computer 
modelling, based on the 3D shape of the selected compounds. While operating in a slightly 
different area of research to the modification of sulfa drugs, this paper nevertheless presents a 
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cogent approach to modification and testing of derivatives using modern laboratory and 
computational techniques. 
 
PREVIOUS WORK IN THIS LAB 
	
The Hearn lab has been investigating the organic chemistry of antitubercular drug design for 
over two decades. Our ongoing partnership with Dr. Michael Cynamon began in 2003 with the 
design, preparation, and biological testing of acylated isoniazid (INH) derivatives. This work 
contributed to emerging literature on the interaction of NAT with INH by probing with acylation 
the primary amine (N2) that makes up the hydrazine portion of the molecule. Six different 
compounds were prepared in our lab, including the acetylated form of INH that is produced after 
its deactivation by NAT. As expected, the N2-acetyl derivative was significantly less active than 
its progenitor against tuberculosis, but some of the other acyl derivatives showed a higher 
activity than expected. Among them was the N2-COCF3 derivative, which was substantially more 
lipophilic than INH and demonstrated an MIC within an order of magnitude of INH's value.46 
Figure 9. N2-acyl derivatives prepared and tested by Hearn & Cynamon, 2003.46 
 Dr. Cynamon also tested the N2-propionyl derivative in vivo, comparing it to an identical 
dose of isoniazid. The N2-propionyl derivative provided “significant levels of protection,” an 
unexpected response due to both its activity in vitro and its similarity to the N2-acetyl metabolite 
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compound. This result suggests the value in the “study of such close structural congeners of 
metabolites.”46 
 Our lab has focused on the modification of antitubercular drugs for many years, in an 
effort to elaborate on their properties and discover potential new antitubercular agents. Our 
research into the modification of sulfa drugs is the latest piece in the larger puzzle of the fight 




We can craft a forward direction for antitubercular drug design that is shaped by this abundance 
of information about sulfa drugs, their mechanism of action, and their metabolism by enzymes. 
Any novel drug would ideally accomplish several improvements over the original sulfa 
compounds: (1) increased efficacy, i.e. activity against MTB; (2) increased bioavailability, 
including resistance to the de-activating effects of NATs; and (3) reduced frequency and severity 
of undesirable side effects. 
The interaction of hydrophobic loop 2 with pABA and therefore with its sulfa drug 
mimics implies that increasing lipophilicity would increase the strength of this interaction and 
perhaps correspondingly boost activity against tuberculosis. Lipophilicity would also improve 
permeability through cell membranes and overall pharmacokinetic properties, a worthy 
consideration in drug design.47 Based on the shape of the binding pocket, modifications should 
be made at the nitrogen of the arylamine (N4). As White and colleagues propose, modifications 
that extend into the DHPP pocket could prevent resistance from developing as easily; they note 
that while the pABA site is tolerant of mutations, the DHPP pocket is “highly conserved and 
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unlikely to tolerate mutations that might decrease binding affinity.”38 Such modifications at N4 
maintain the possibility of decreasing allergic reaction to sulfa drug treatment. 
Blocking N4 with a substituent such as an acyl group should also prevent de-activation by 
NATs. We know such compounds are stable because they are similar to the metabolized form of 
the drug; our lab’s work with INH derivatives suggests we may be able to achieve a surprising 
level of increased activity. Also note that the hydrazine moiety is implicated in INH’s 
mechanism of action – it must be removed to form the active structure – which may explain the 
decrease in activity when it is acylated.46 While sulfa drugs’ N4 atom is the nexus for their 
conjugation to DHPP, sulfa drugs are not a pro-drug like INH and therefore may experience a 
different effect on their activity. When this possibility to avoid NATs is taken together with our 
knowledge of the mechanism of DHPS, acylation seems like an excellent starting place to probe 





MATERIALS AND METHODS 
	
 General methods. Elemental analyses were carried out by Galbraith Laboratories, 
Knoxville, Tennessee, or by Robertson Microlit Laboratories, Ledgewood, New Jersey. All new 
compounds gave satisfactory elemental analyses for carbon, hydrogen and nitrogen. In a number 
of cases, it was also useful to obtain satisfactory elemental analyses for known compounds. 
Melting points (mp, °C) were taken in open capillary tubes using a Mel-Temp apparatus 
(Laboratory Devices, Cambridge, Massachusetts), and are uncorrected. Due to recently 
implemented institutional safety requirements on the use of mercury, some melting points were 
taken using alcohol thermometers and thus recorded only as high as 260	°C.  From the earliest 
days of research on their preparation, it has been well-known that sulfa compounds display 
polymorphisms and often form solvates of crystallization; these phenomena may influence the 
apparent physical properties of compounds prepared in different laboratories.48 Infrared (IR) 
spectra were recorded on a Perkin-Elmer Spectrum One Fourier transform spectrophotometer 
fitted with a universal attenuated total reflectance sampling accessory, reported in wavenumbers 
(𝜈, cm–1). Nuclear magnetic resonance (NMR) spectra were taken on a Bruker Avance 500 
Fourier transform instrument as dilute solutions in dimethyl sulfoxide-d6 (DMSO-d6) or 
chloroform-d, recorded at 500 megahertz (1H NMR) or 125 megahertz (13C NMR) and are 
reported in parts per million delta (d) downfield from internal tetramethylsilane (TMS) as 
reference; common vicinal aromatic coupling constants (J) were in the range of 7-9 Hz; common 
vicinal aliphatic coupling constants were in the range of 5-7 Hz. In some proton spectra, only 
signals in the region 0-10 ppm are reported. Appropriate solvent blanks were recorded to account 
for water and DMSO. Hard copies of original infrared spectra, magnetic resonance spectra and 
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elemental analysis reports are maintained by the principal investigator and are available upon 
request. 
 Reactants, reagents and solvents were obtained from Sigma-Aldrich Chemical Company 
(Milwaukee, Wisconsin) and Alfa Aesar Incorporated (Windham, New Hampshire) and were 
used as received. Reactions were conveniently carried out on 10 mmole scale in a 100 mL round 
bottom flask fitted for reflux with a temperature-controlled heating mantle, magnetic stirrer and 
reflux condenser, using approximately 20 mL of solvent as specified in the individual 
procedures.  Unless otherwise noted, ethanol refers to absolute ethanol. 
 Once satisfactory protocols were obtained for a given reaction, no further attempt was 
made to optimize yields. Calculated values of the logarithms of the partition coefficients (C log P 
values) were obtained using the QSAR properties function of ChemDraw, following geometry 
optimization of structures.  
 Safety Notes: Gloves and eye protection were worn during the chemical syntheses, and 
the reactions were carried out in the hood. In general, any scale-up of preparations of compounds 
with relatively high proportions of nitrogen and oxygen was done with due caution. No specific 
safety problems were encountered with our methods.   
 
     Biological assessments. The assessments were performed through the collaboration of Dr. 
Michael H. Cynamon, Chief, Infectious Diseases, Veterans Affairs Medical Center, Syracuse, 
New York. For initial screening, Kirby-Bauer disk diffusion testing was used.49 As a 
representative example, we give here in brief the protocol for screening against M. bovis BCG 
Tice. The test compounds (20 mg) were dissolved in enough DMSO to prepare solutions that had 
a concentration of 20 mg/mL. The solutions were then applied to 6-mm filter paper disks such 
	 40 
that the total weight of test compound per disk was 200 micrograms. The disks were laid on 
7H10 agar plates having a cell density of M. bovis BCG Tice of three MacFarland units. M. bovis 
BCG Tice was obtained from the American Type Culture Collection (ATCC, Manassas, 
Virginia). The plates were incubated at 37 ºC for seven days and then read using transmitted 
light. The antimicrobial activity of the compound was measured by the dimensions of the 
circular clear zone surrounding the disk in which no growth occurred, while the remainder of the 
plate showed a luxuriant bacterial lawn, as did control plates containing no drug. 
 For the determination of minimum inhibitory concentrations, the experimental protocols 
have been fully documented.50 In brief, M. tuberculosis ATCC 35801 (strain Erdman) was 
obtained from the ATCC. The reference standard isonicotinic acid hydrazide (INH) was 
purchased from Sigma Chemical Company (St. Louis, Missouri). For testing, a given compound 
was dissolved in dimethyl sulfoxide and subsequently diluted in distilled water. The positive 
control INH was dissolved in distilled water. Stock solutions were filter-sterilized by passage 
through a 0.22 µm-pore-size membrane filter and stored at -20 oC until use. The drug solutions 
were prepared each morning, before experimentation. With respect to testing against the above 
isolate, the minimum inhibitory concentrations (MICs) of all antimicrobial agents were 
determined in modified 7H10 broth (7H10 agar formulation with agar and malachite green 
omitted; pH 6.6) supplemented with 10% Middlebrook oleic acid-albumin-dextrose-catalase 
(OADC) enrichment (Difco Laboratories, Detroit, Michigan) and 0.05% Tween 80.51 The 
activities of the antimicrobial agents were determined by a broth dilution method.52 The 
organism was grown in the modified 7H10 broth with 10% OADC enrichment and 0.05% Tween 
80 on a rotary shaker at 37 oC for 5 days. The culture suspension was diluted in modified 7H10 
broth to yield 100 Klett units/mL (Photoelectric Colorimeter, Manostat Corporation, New York, 
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New York), or approximately 5 x 107 cfu/mL, where cfu is the abbreviation for colony-forming 
units. The size of the inoculum was determined by titration and counting from triplicate 7H10 
agar plates (BBL Microbiology Systems, Cockeysville, Maryland) supplemented with 10% 
OADC enrichment. The plates were incubated at 37 oC in ambient air for 4 weeks before 
counting of the colonies. The use of M. tuberculosis Erdman for determinations of MIC values is 









In a procedure representative of the preparation of the following sulfa drug metabolites, glacial 
acetic acid (5 mL) was placed in a 100 mL round bottom flask fitted with a magnetic stirrer and 
voltage-regulated heating mantle. The liquid was warmed to 85 °C. Sulfabenzamide (1.38 g, 5.00 
mmol) was added to the warm acid with rapid stirring to form a clear colorless solution (1.0 M). 
Slow dropwise addition of acetic anhydride (0.56 g, 5.50 mmol, 1.1 equiv) in acetic acid (5 mL) 
over 20 minutes was followed by warming and stirring for another hour.  Distilled water (40 mL) 
was added, and the mixture was cooled to room temperature. Filtration and drying of the 
abundant white crystalline product led to the title compound, the N4-acetyl metabolite, 1.52 g 
(96%). The analytical sample was readily obtained by recrystallization from ethanol, mp 245 °C.  
FT-IR: nmax 3312, 3276, 3120, 3058, 1696, 1604, 1589, 1265, 1161 cm -1 
1H-NMR (DMSO-d6): d 12.43 (brs, 1H), 10.40 (s, 1H), 7.95-7.93 (m, 2H), 7.87-7.85 (m 2H), 
7.81-7.80 (m, 2H), 7.65-7.60 (m, 1H), 7.50-7.47 (m, 2H), 2.09 (s, 3H) 
13C-NMR (ppm, DMSO-d6): d 168.52, 164.74, 143.27, 132.60, 132.13, 130.95, 128.53, 127.98, 
127.76, 117.77, 23.55 
 Anal.  Calcd for C15H14N2O4S: C, 56.59; H, 4.43; N, 8.80. 






Yield: 1.33 g (86%),  mp 248 °C,  lit mp 249-251 °C54 
FT-IR:  nmax 3312, 3284, 3060, 2871, 1696, 1604, 1187, 1158 cm -1 
1H-NMR (DMSO-d6): d 11.96 (brs, 1H), 10.38 (brs, 1H), 7.84 (d, 2H), 7.77 (d, 2H), 2.09 (s, 3H),  
1.91 (s, 3H) 
13C-NMR (ppm, DMSO-d6): d 168.55, 168.07, 143.17, 132.11, 128.26, 117.79, 23.53, 22.58. 
 Anal. Calcd for C10H12N2O4S: C, 46.87; H, 4.72; N, 10.93. 








Yield: 1.04 g (81%),  mp 248-250 °C,  lit mp 249-251 °C55 
FT-IR:  nmax 3342, 3020, 2727, 1671, 1591, 1528, 1492, 1299, 1154   cm -1 
1H-NMR (DMSO-d6): d 11.58 (brs, 1H), 10.28 (s, 1H), 7.90 (d, 2H), 7.72 (d, 2H), 6.75 (s, 1H), 
2.24 (s, 6H), 2.07 (s, 3H)   



















Yield: 1.43 g (94%), mp 246-247 °C, lit mp 245-246 °C56 
FT-IR:  nmax  3536, 3087, 3042, 2719, 1661, 1590, 1565, 1540, 1493, 1398, 1373, 1271, 1241, 
1187, 1160   cm -1 
1H-NMR (DMSO-d6): d 11.60 (brs, 1H), 10.30 (s, 1H), 8.30 (d, J = 4 Hz, 1H), 7.93 (d, 2H), 7.74 
(d, 2H), 6.89 (d, J = 4 Hz, 1H), 2.30 (s, 3H), 2.07 (s, 3H)      
13C-NMR (ppm, DMSO-d6): d 169.47, 168.70, 158.00, 157.04, 143.53, 134.43, 129.53, 118.50, 
115.30, 24.58, 23.71   
  
	 46 
V N4-Acetylsulfadiazine   
CH3
	
Yield: 1.37 g (94%),  mp 253-254 °C (ethanol),  lit mp 253-254 °C57 
FT-IR:  nmax 3603, 3309, 3036, 2943, 2730, 1674, 1580, 1537, 1486, 1444, 1405, 1373, 1333, 
1324, 1272, 1264, 1159, 1091, 1040  cm -1 
1H-NMR (DMSO-d6): d 11.68 (brs, 1H), 10.31 (s, 1H), 8.49 (d, J = 4 Hz, 2H), 7.92 (d, 2H), 7.75 
(d, 2H), 7.03 (m, 1H), 2.06 and 2.07 (overlapping singlets, 3H)   
13C-NMR (ppm, DMSO-d6): d 169.50, 158.80, 157.40, 143.65, 134.26, 129.33, 118.67, 116.13, 







VI N4-Acetylsulfathiazole   
CH3
	
Yield: 1.35 g (91%), mp 262-263 °C (ethanol), lit mp 250 °C58 
FT-IR:  nmax 3288, 3246, 3153, 3108, 3064, 2979, 2906, 1670, 1604, 1590, 1518, 1491, 1407, 
1396, 1372, 1321, 1300, 1264, 1173, 1144, 1117, 1088 cm -1. This spectrum was a good match 
with that of an authentic sample, as reported.59 
1H-NMR (DMSO-d6): d 12.66 (brs, 1H), 10.25 (s, 1H), 7.72 (aromatic pseudo-quartet, two 
overlapping doublets, 4H), 7.24 (d, 1H), 6.81 (d, 1H), 2.07 (s, 3H)   











VII N4-Acetylsulfanilamide    
H2N CH3
	
Yield: 0.62 g (59%), mp 214 °C, lit mp 211-212 °C60, lit mp 215-216 °C61 
FT-IR:  nmax 3342, 3296, 3248, 1661, 1591, 1520, 1399, 1370, 1289, 1264, 1153, 1096, 1074, 
908 cm -1. This spectrum was a good match with that of an authentic sample, as reported.62 
1H-NMR (DMSO-d6): d 10.26 (s, 1H), 7.76 (aromatic pseudo-quartet, two overlapping doublets, 
4H), 7.23 (s, 2H), 2.08 (s, 3H)      
13C-NMR (ppm, DMSO-d6): d 169.38, 142.66, 138.53, 127.15, 118.91, 24.58 
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PREPARATION OF N4-ACYLATED SULFA DRUGS 
	
These materials constitute the family of N4-acylated sulfa compounds that are not NAT 







In a procedure representative of the preparation of the following N4-acylated sulfa compounds 
(VIII-XIV), valeric acid (10 mL) was placed in a 100 mL round bottom flask fitted with a 
magnetic stirrer and voltage-regulated heating mantle. The liquid was warmed to 80 °C and rapid 
stirring was begun. To the warm stirred liquid was added sulfamethazine (1.39 g, 5.00 mmol). 
The sulfamethazine did not all dissolve, but it did form a tractable slurry. Valeric anhydride (1.02 
g, 5.50 mmol, 1.1 equiv) was added dropwise at a rapid rate. Within less than 2 minutes after the 
completion of the addition of the anhydride, all of the white slurry had dissolved, and there was a 
homogeneous yellow solution. During the addition of the anhydride, the temperature had risen; it 
was now maintained at 105 °C over the course of an hour. Heating was stopped, and the reaction 
mixture was cooled to near room temperature using a cool water bath. The mixture was poured 
onto 50 g of chipped ice in a large beaker and allowed to stand overnight. The resulting white 
solid was filtered off, and a second crop was obtained from the mother liquor, 1.41 g (78%).  The 
analytical sample was obtained by recrystallization from ethanol, mp 171-172 °C.  
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FT-IR: nmax  3278, 3237, 3178, 3120, 3098, 3066, 2955, 2924. 1658, 1624, 1586, 1540, 1399, 
1271, 1141, 1119, 1076 cm -1 
1H-NMR (DMSO-d6): d  11.57 (brs, 1H), 10.22 (s, 1H), 7.94-7.92 (d, 2H), 7.75-7.73 (d, 2H), 
6.72 (s, 1H), 2.32 (t, 2H), 2.24 (s, 6H), 1.55 (quint, 2H), 1.30 (sextet, 2H), 0.87 (t, 3H).  
13C-NMR (ppm, DMSO-d6): d  172.42, 156.69, 143.41, 134.61, 129.73, 118.36, 114.02, 36.63, 
27.52, 23.33, 22.23, 14.14 
 Anal.  Calcd for C17H22N4O3S: C, 56.33; H, 6.12; N, 15.46. 







Yield: 2.99 g (86%, 10.0 mmol scale),  mp 191-193°C,  lit mp 189-190 °C63 
FT-IR:  nmax  3325, 3200, 3020, 2958, 2949, 2936, 2866, 1672, 1586, 1560, 1531, 1475, 1436,  
1397, 1334, 1313, 1247, 1189, 1156, 1092, 1036, 960 cm -1 
1H-NMR (DMSO-d6): d  11.59 (brs, 1H), 10.25 (s, 1H), 8.32 (d, 1H), 7.92 (d, 2H), 7.75 (d, 2H),  
6.90 (d, 1H), 2.35-2.31 (m consisting of triplet and singlet, 5H), 1.55 (quintet, 2H), 1.32 (sextet,  
2H), 0.88 (t, 3H)       
13C-NMR (ppm, DMSO-d6): 
d 172.45, 168.69, 158.0, 157.03, 143.56, 134.36, 129.51, 118.55, 115.31, 36.63, 27.52, 23.71,  
22.22, 14.15       
 Anal. Calcd for C16H20N4O3S: C, 55.16; H, 5.79; N, 16.08. 
    Found:  C, 54.87; H, 5.83; N, 15.90.  
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X  N4-Valeroylsulfadiazine 
CH2CH2CH2CH3
 
Yield: 3.17  g (95%, 10.0 mmol scale),  mp 218-219 °C,  lit mp 222-223 °C63 
FT-IR: nmax  3376, 3083,  3031,  2949, 2926, 2867, 2855, 2807, 2731,  1685, 1580, 1484, 1441, 
1401, 1333, 1304, 1266, 1251, 1187, 1164, 1092, 937 cm -1 
1H-NMR (DMSO-d6): d  11.67 (brs, 1H), 10.26 (s, 1H), 8.50 (d, 2H), 7.92 (d, 2H), 7.77 (d, 2H), 
7.04 (t, 1H),  2.34 (t, 2H), 1.57 (quint, 2H), 1.32 (sextet, 2H), 0.88 (t, 3H).  
13C-NMR (ppm, DMSO-d6): d  171.43,  157.75, 156.34, 142.63, 133.14, 128.27, 117.66, 115.19, 
35.59, 26.47, 21.16, 13.10 
 Anal.  Calcd for C15H18N4O3S . 0.25 H2O: C, 53.16; H, 5.50; N, 16.53. 
                                  Found:  C, 53.45; H, 5.48; N, 16.72. 
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XI  N4-Valeroylsulfathiazole 
CH2CH2CH2CH3
 
Yield: 3.27  g (96%, 10.0 mmol scale),  mp 220-221 °C,  lit mp 212-213°C63 
FT-IR: nmax  3346, 3312, 3146, 3129, 3109, 3096, 3020, 2969, 2860, 2807,  1667, 1519, 1416, 
1397, 1335, 1308, 1281, 1250, 1141, 1115, 1083, 938  cm -1 
1H-NMR (DMSO-d6): d  12.3 (very brs), 10.21 (s, 1H), 7.75 (apparent s, 4H), 7.25 (d, 2H), 6.82  
(d, 2H),  2.35 (t, 2H), 1.57 (quint, 2H), 1.33 (sextet, 2H), 0.89 (t, 3H).  
13C-NMR (ppm, DMSO-d6): d  172.34,  169.15, 142.94, 136.50, 127.38, 124.83, 118.95, 108.52, 
36.63, 27.55, 22.23, 14.15 
 Anal.  Calcd for C14H17N3O3S2:  C, 49.54; H, 5.05; N, 12.38. 








Yield: 0.78  g (52%),  mp 216 °C 
FT-IR: nmax  3310, 3276, 3188, 3083, 2954, 2872, 2807, 1714 (sh), 1676, 1590, 1529, 1467, 
1400, 1337, 1310, 1233, 1152, 1092, 996 cm -1 
1H-NMR (DMSO-d6): d  11.95 (brs, 1H), 10.32 (s, 1H), 7.84 (d, 2H), 7.79 (d, 2H),  2.35 (t, 2H),  
1.91 (s, 3H), 1.57 (quint, 2H), 1.35 (sextet, 2H), 0.89 (t, 3H) 
13C-NMR (ppm, DMSO-d6): d  172.55, 169.09, 144.29, 133.12, 129.32, 118.88, 36.66, 27.51, 
23.64, 22.22, 14.16  
 Anal.  Calcd for C13H18N2O4S:  C, 52.33; H, 6.08; N, 9.39. 
                 Found:  C, 51.93; H, 5.98; N, 9.23. 
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XIII  N4-Valeroylsulfabenzamide 
CH2CH2CH2CH3
 
Yield: 1.63  g (91%),  mp 219 °C 
FT-IR: nmax  3344, 3070, 3059, 2957, 2928, 2861, 1669, 1587, 1534, 1468, 1401, 1337, 1250, 
1187, 1159, 1093, 965  cm -1 
1H-NMR (DMSO-d6): d  12.44 (brs, 1H), 10.34 (s, 1H), 7.91 (d, 2H), 7.84-7.46 (m, 7H), 2.35 (t, 
2H),  1.57 (quint, 2H), 1.32 (sextet, 2H), 0.87 (t, 3H) 
13C-NMR (ppm, DMSO-d6): d  172.60, 165.82, 144.38, 133.64, 133.15, 132.01, 129.59, 129.03, 
128.82, 118.90, 36.68, 27.51, 22.22, 14.14  
 Anal.  Calcd for C18H20N2O4S:  C, 59.98; H, 5.59; N, 7.77. 
                 Found:  C, 59.66; H, 5.70; N, 7.77. 
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XIV  N4-Valeroylsulfanilamide 
CH2CH2CH2CH3
 
Yield: 1.55  g (61%, 10.0 mmol scale),  mp 208-209 °C 
FT-IR: nmax  3364, 3318, 3199, 3128, 2958,  2934, 2874, 2859, 1669, 1591, 1527, 1401, 1328, 
1151, 1096  cm -1 
1H-NMR (DMSO-d6): d  10.20 (s, 1H), 7.74 (apparent singlet, 4H), 7.23 (s, 2H), 2.35 (t, 2H),  
1.58 (quint, 2H), 1.33 (sextet, 2H), 0.87 (t, 3H) 
13C-NMR (ppm, DMSO-d6): d  172.36, 142.67, 138.49, 127.11, 118.96, 36.62, 27.55, 22.25, 
14.18   
 Anal.  Calcd for C11H16N2O3S:  C, 51.54; H, 6.29; N, 10.93. 
                 Found:  C, 51.52; H, 6.22; N, 10.87. 
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XV  N4-Benzoylsulfamethazine 
CH3
CH3  
Pyridine (10 mL) was placed in a 100 mL round bottom flask fitted with a magnetic stirrer and 
voltage-regulated heating mantle. The liquid was warmed to 70 °C and rapid stirring was begun. 
To the warm stirred liquid was added sulfamethazine (1.39 g, 5.00 mmol) in several portions, 
creating a homogeneous yellow solution. The warm solution was stirred vigorously as benzoyl 
chloride (0.70 g, 5.00 mmol) was added dropwise in a rapid manner. There was a distinct 
exotherm. The mixture was stirred for 30 minutes, at the end of which time the temperature was 
70 °C. The mixture was cooled to near ambient temperature in a cool water bath, then poured 
onto 75 g of chipped ice. This produced a white precipitate. The mixture was allowed to stand 
several hours. The solid was filtered off and allowed to dry for several days. The solid was then 
recrystallized from ethanol (105 mL), dried on the filter and then dried in vacuo.    
Yield: 1.77  g (93%),  mp 237 °C, lit mp 233-235 °C63 The 1H-NMR spectrum was identical to 
the spectrum obtained online on SciFinder under the entry for the title compound (see below).   
FT-IR: nmax  3345, 3067, 2948, 2784, 1661, 1593, 1526, 1400, 1316, 1187, 1156, 1090,  
1071 cm -1 
1H-NMR (DMSO-d6): d  11.65 (very brs, 1H), 10.57 (s, 1H), 8.01-7.52 (m, 9H), 6.73 (s, 1H), 
2.25 (s, 6H)      
13C-NMR (ppm, DMSO-d6): d  167.84, 166.49, 156.72, 143.32, 135.42, 134.91, 132.39, 129.57, 





Sulfamethazine (1.39 g, 5.00 mmol) was weighed into a 50 mL pear-shaped flask fitted with a 
heating mantle and mixed with pyridine (4 mL). The mixture was brought to 80 °C to produce a 
clear slightly yellow solution. To this warm mixture was added 4-phenylbenzoyl chloride (1.09 
g, 5.00 mmol) in several portions with swirling after each addition. Finally, the last of the acid 
chloride was washed in with pyridine (2 mL). The mixture was maintained at 80 °C for 45 
minutes. Heating was stopped, and the mixture was poured onto 150 mL of chipped ice. The 
material was allowed to stand overnight to produce a voluminous white crystalline solid. The 
solid was filtered off and washed with ether (10 mL, then 3 x 5 mL) and allowed to dry to a 
white free-slowing solid. The analytical sample was easily recrystallized from ethanol (45 mL). 
Yield: 2.20 g (96%), mp  242-243 °C 
FT-IR: nmax  3280, 3031, 1651, 1590, 1522, 1511, 1397, 1381, 1306, 1159, 1089, 1072 cm -1 
1H-NMR (DMSO-d6): d  11.5 (very brs, 1H), 10.6 (s, 1H), 8.08-7.41 (m, 13H), 6.75 (s, 1H), 2.25 
(s, 6H)  
13C-NMR (ppm, DMSO-d6): d  164.98, 155.68, 142.85, 139.40, 132.56, 128.50, 128.47, 127.92, 
127.60, 126.34, 126.04, 118.61, 22.30. There was considerable fortuitous overlap of peaks in the 
aromatic region. The number of peaks and relative positions, however, corresponded to the 
calculated values at the website of cheminfo.org.64 
 Anal.  Calcd for C25H22N4O3S:  C, 65.48; H, 4.84; N, 12.22. 




Pyridine (20 mL) was placed in a 100 mL round bottom flask fitted with a magnetic stirrer and 
voltage-regulated heating mantle. The liquid was warmed to 70 °C and rapid stirring was begun. 
To the warm stirred liquid was added sulfathiazole (2.55 g, 10.0 mmol) in several portions, 
creating a homogeneous yellow solution. The warm solution was stirred vigorously as benzoyl 
chloride (1.40 g, 10.0 mmol) was added dropwise in a rapid manner. There was a distinct 
exotherm. The mixture was stirred and warmed for 30 minutes, at the end of which time the 
temperature was 70 °C. The mixture was cooled to near ambient temperature in a cool water 
bath, then poured onto 150 g of chipped ice. This produced a white precipitate. The mixture was 
allowed to stand overnight. The solid was filtered off and gave 3.72 g of a slightly damp mass.  
The solid was then washed with 150 mL of boiling ethanol for 10 minutes, then filtered and 
dried. A small amount of material also crystallized from the ethanol.     
Yield: 3.28 g (91%), mp >260 °C  
FT-IR: nmax  3392, 3323, 3144, 3116, 3100, 3053, 3019, 2962, 2899, 2808, 1674, 1654 (sh), 
1590, 1574, 1520 (sh), 1399 1323, 1292, 1256, 1144, 1116, 1086, 935 cm -1 
1H-NMR (DMSO-d6): d  12.71 (s, 1H), 10.56 (s, 1H), 7.97-7.53 (m, 9H), 7.26 (d, 1H), 6.83 (d, 
1H)     
13C-NMR (ppm, DMSO-d6): d  169.22, 166.43, 142.89, 137.20, 134.98, 132.36, 128.92, 128.25, 
127.27, 124.89, 120.26, 108.59 
 Anal.  Calcd for C16H13N3O3S2:  C, 53.47; H, 3.65; N, 11.69. 
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The preparation of this compound was done from the reaction of sulfathiazole with lauroyl 
chloride and was carried out in a manner similar to that of compound XVII.  
Yield: 3.18 g (73%, 10.0 mmol scale),  mp 167-168 °C, lit mp 165-167 °C63, lit mp 166 °C65 
FT-IR: nmax  3311, 3145, 3004, 2954, 2915, 2847, 1666, 1596, 1565, 1517, 1398, 1296, 1247, 
1176, 1146, 1089, 937 cm -1 
1H-NMR (DMSO-d6): d  12.8 (brs, 1H), 10.2 (s, 1H), 7.73 (apparent singlet, 4H), 7.24 (d, 1H), 
6.80 (d, 1H), 2.32 (t, 2H), 1.56 (quintet, 2H), 1.24 (m, 16H), 0.83 (t, 3H)     
13C-NMR (ppm, DMSO-d6): d  172.26, 169.13, 142.96, 136.51, 127.35, 124.82, 118.90, 108.47, 





The preparation of this compound was done from the reaction of sulfathiazole with 3-
chlorobenzoyl chloride and was carried out in a manner similar to that of compound XVII.  
Yield: 3.43 g (87%, 10.0 mmol scale),  mp 224-226 °C    
FT-IR: nmax  3360, 3092, 3058, 3013, 1664, 1588, 1571, 1519, 1314, 1248, 1142, 1077, 938 cm -1 
1H-NMR (DMSO-d6): d  12.71 (brs, 1H), 10.63 (s, 1H), 8.01-7.56 (m, 8H), 7.25 (d, 1H), 6.83 (d, 
1H)      
13C-NMR (ppm, DMSO-d6): d  169.25, 164.93, 142.57, 137.48, 136.92, 133.72, 132.17, 130.92, 
127.99, 127.29, 127.09, 124.85, 120.37, 108.60  
 Anal.  Calcd for C16H12ClN3O3S2:  C, 48.79; H, 3.07; N, 10.67. 








The preparation of this compound was done from the reaction of sulfacetamide with lauroyl 
chloride and was carried out in a manner similar to that of compound XVII. The material was 
easily recrystallized from ethanol.   
Yield: 3.11 g (78%, 10.0 mmol scale),  mp 151-153 °C    
FT-IR: nmax  3346, 3284, 2952, 2919, 2850, 1723 (sh), 1690, 1590, 1514, 1433, 1400, 1331, 
1209, 1154, 1091, 941 cm -1 
1H-NMR (DMSO-d6): d  11.95 (brs, 1H), 10.31 (s, 1H), 7.85 (d, 2H), 7.79 (d, 2H),  2.34 (t, 2H), 
1.90 (s, 3H), 1.58 (quintet, 2H), 1.22 (m, 16H), 0.84 (t, 3H)          
13C-NMR (ppm, DMSO-d6): d  172.50, 169.03, 144.31, 133.11, 129.29, 118.83, 36.94, 31.77, 
29.49, 29.47, 29.40, 29.26, 29.19, 29.08, 25.39, 23.62, 22.56, 14.36  
 Anal.  Calcd for C20H32N2O4S:  C, 60.58; H, 8.13; N, 7.06. 






The preparation of this compound was done from the reaction of sulfathiazole with 
cyclobutanecarbonyl chloride and was carried out in a manner similar to that of compound XVII.  
Yield: 2.78 g (82%, 10.0 mmol scale),  mp >260 °C    
FT-IR: nmax  3320, 3145, 3117, 2990, 2941, 1672, 1593, 1559, 1528, 1518, 1399, 1293, 1179, 
1145, 1085, 935 cm -1 
1H-NMR (DMSO-d6): d  12.66 (brs, 1H), 10.04 (s, 1H), 7.76-7.71 (aromatic pseudo-quartet, 
overlapping doublets, 4H), 7.24 (d, 1H), 6.81 (d, 1H), 3.20 (quintet, 1H), 2.25-1.76 (m, 6H)      
13C-NMR (ppm, DMSO-d6): d  173.89, 169.12, 143.01, 136.49, 127.36, 124.85, 119.03, 108.51, 
25.00, 18.14 (one high field signal is coincident with the solvent peak, calculated value 39.764)   
 Anal.  Calcd for C14H15N3O3S2:  C, 49.83; H, 4.48; N, 12.45. 





The preparation of this compound was done from the reaction of sulfathiazole with 
cyclohexanecarbonyl chloride and was carried out in a manner similar to that of compound 
XVII.  
Yield: 2.57 g (70%, 10.0 mmol scale),  mp 227-228 °C    
FT-IR: nmax  3315, 2021, 2851, 1665, 1586, 1571, 1539, 1522, 1398, 1289, 1146, 1120 cm -1 
1H-NMR (DMSO-d6): d  12.66 (brs, 1H), 10.13 (s, 1H), 7.75-7.71 (aromatic pseudo-quartet, 
overlapping doublets, 4H), 7.24 (d, 1H), 6.81 (d, 1H), 2.33 (m, 1H), 1.80-1.20 (m, 10H)       
13C-NMR (ppm, DMSO-d6): d  175.28, 169.14, 143.13, 136.42, 127.35, 124.86, 118.97, 108.51, 
45.34, 29.48, 25.81, 25.62   
 Anal.  Calcd for C14H15N3O3S2:  C, 52.58; H, 5.24; N, 11.49. 






The preparation of this compound was done from the reaction of sulfabenzamide with lauroyl 
chloride and was carried out in a manner similar to that of compound XVII. The material was 
easily recrystallized from ethanol.   
Yield: 3.60 g (79%, 10.0 mmol scale),  mp 208 °C    
FT-IR: nmax  3327, 3298, 3243, 3114, 3068, 3042, 2953, 2915, 2848, 1708 (sh), 1685, 1590, 
1528, 1497, 1457, 1437, 1403, 1350, 1322, 1188, 1163, 1117, 1087, 927 cm -1 
1H-NMR (DMSO-d6): d  12.42 (brs, 1H), 10.32 (s, 1H), 7.94-7.46 (m, 9H),  2.34 (t, 2H), 1.58 
(quintet, 2H), 1.22 (m, 16H), 0.83 (t, 3H)          
13C-NMR (ppm, DMSO-d6): d  172.53, 165.79, 144.35, 133.60, 133.19, 132.08, 129.57, 129.00, 
128.82, 118.84, 36.95, 31.75, 29.47, 29.44, 29.37, 29.24, 29.17, 29.06, 25.38, 22.55, 14.39   
 Anal.  Calcd for C25H34N2O4S:  C, 65.47; H, 7.47; N, 6.10. 





The preparation of this compound was done from the reaction of sulfabenzamide with 3-
chlorobenzoyl chloride and was carried out in a manner similar to that of compound XVII.  
Yield: 3.93 g (95%, 10.0 mmol scale),  mp 251 °C    
FT-IR: nmax  3291, 3062, 1690 (sh), 1656, 1591, 1515, 1496, 1452, 1420, 1398, 1316, 1166, 
1056 cm -1 
1H-NMR (DMSO-d6): d  12.50 (brs, 1H), 10.76 (s, 1H), 8.05-7.47 (m, 13H)       
13C-NMR (ppm, DMSO-d6): d  165.87, 165.14, 144.06, 136.81, 134.14, 133.75, 133.70, 132.28, 
132.01, 130.93, 129.46, 129.06, 128.87, 128.06, 127.16, 120.30   
 Anal.  Calcd for C20H15ClN2O4S:  C, 57.90; H, 3.64; N, 6.75. 







PREPARATION OF N1,N4-DIACYLATED SULFA DRUGS 
In general, these compounds were prepared by the controlled sequential acylation, in order, of N4 
and N1. The N4-acyl materials were isolated and fully characterized, then subjected to a second 
acylation at N1. This permitted considerable variation of the acyl groups at each position. The 
exceptions to this were the preparations of XXV and XXVI, in which a large excess of acylating 
agent was used under vigorous conditions to prepare the diacyl compound (N1,N4 substituents 






In a 100 mL round bottom flask fitted for magnetic stirring and reflux, acetic anhydride (20 mL) 
was mixed with sulfanilamide (1.72 g, 10.0 mmol). Upon stirring and good mixing, the beige 
chunky sulfanilamide was rapidly replaced with a white microcrystalline solid. The mixture was 
brought to reflux. After 10 minutes at the boil, the white crystalline solid had dissolved to form a 
clear homogeneous solution. The mixture was refluxed for 90 minutes, cooled and the excess 
anhydride evaporated to give a white solid. This was washed with ether (20 mL), then covered 
with a fresh portion of ether (20 mL) and allowed to stand for 5 hours. The solid was filtered to 
give the title compound (2.15 g, 84%), identical (FT-IR) to the authentic specimen prepared by 
the N4-acetylation of sulfacetamide (compound II, thus the metabolite of sulfacetamide), as 
previously described, and to the compound described in SciFinder under CAS Registry Number 
5626-90-4. If desired, the compound could be readily recrystallized from ethanol; however, the 
	 69 
purity was not further improved by recrystallization; viz., the ether washes were sufficient to give 









Sulfamethazine (1.00 g, 3.6 mmoles) was weighed into a 50 mL pear-shaped flask fitted with a 
heating mantle. Pyridine (4 mL) was added and the mixture was warmed until a homogeneous 
slightly yellow solution was obtained. Acetic anhydride (1.84 g, 18.0 mmol, 5.00 equiv) was 
added to the warm solution in several portions and washed in with further pyridine (1 mL). The 
mixture was brought to the boil. Within several minutes, the mixture became milky in 
appearance and a solid was suspended within the liquid. After 10 minutes, a white solid had 
deposited. Refluxing was continued for an hour. Heating was stopped and the mixture allowed to 
cool and stand overnight. The solvent was evaporated. The resulting beige mass was washed 
with portions of ether (20 mL, then 5 mL) and dried. The analytical sample was obtained by 
recrystallization from ethanol. The following characterization data made it clear that N1,N4-
diacetylation had indeed occurred and that the compound was not merely N4-monoacetylated 
(compare data for compound III).  
Yield: 1.08 g (83%),  mp 239-240 °C,  lit mp 237-238 °C (dimethylacetamide, water)66 
FT-IR: nmax  3320, 3281, 3187, 3118, 1705 (sh), 1688, 1600, 1583, 1527, 1400, 1362, 1315, 
1260, 1186, 1164, 1113, 1086, 1023  cm -1 
1H-NMR (DMSO-d6): d  10.47 (s, 1H), 8.03 (d, 2H), 7.84 (d, 2H), 7.47 (s, 1H), 2.54 (s, 6H), 
2.11 (s, 3H), 1.81 (s, 3H)  
13C-NMR (ppm, DMSO-d6): d  170.32, 169.75, 168.90, 156.31, 144.82, 132.46, 130.49, 121.12, 








Compound VIII (N4-valeroylsulfamethazine 0.58 g, 1.60 mmol) was weighed into a 50 mL pear-
shaped flask fitted with a heating mantle. Pyridine (4 mL) was added and the mixture was 
warmed until a homogeneous slightly yellow solution was obtained. Acetic anhydride (1.84 g, 
18.0 mmol, 11.25 equiv) was added to the warm solution in several portions and washed in with 
further pyridine (1 mL). The mixture was brought to the boil. Refluxing was continued for an 
hour. Heating was stopped and the mixture allowed to cool and stand overnight. The solvent was 
evaporated. The resulting beige mass was washed with portions of ether (3 x 10 mL) and dried.  
Yield: 0.60 g (93%),  mp 165 °C 
FT-IR: nmax  3313, 3279, 3120, 2954, 2935, 2871, 1686, 1594, 1582, 1526, 1364, 1256, 1184, 
1163, 1115, 920 cm -1 
1H-NMR (DMSO-d6): d  10.40 (s, 1H), 8.04 (d, 2H), 7.87 (d, 2H), 7.45 (s, 1H), 2.54 (s, 6H), 
2.38 (t, 2H), 1.81 (s, 3H), 1.59 (quintet, 2H), 1.33 (sextet, 2H), 0.90 (t, 3H)   
13C-NMR (ppm, DMSO-d6):  d  170.9, 168.87, 156.35, 144.88, 132.40, 130.50, 121.08, 118.81, 
39.45 (obscured by solvent), 36.71, 27.50, 24.26, 23.70, 22.23, 14.15  
 Anal.  Calcd for C19H24N4O4S: C, 56.42; H, 5.98; N, 13.85. 










Compound VIII (N4-valeroylsulfamethazine 0.58 g, 1.60 mmol) was weighed into a 50 mL pear-
shaped flask fitted with a heating mantle. Pyridine (4 mL) was added and the mixture was 
warmed until a homogeneous slightly yellow solution was obtained. Propionic anhydride (1.04 g, 
8.00 mmol, 5.00 equiv) was added to the warm solution in several portions in a rapid dropwise 
manner and washed in with further pyridine (1 mL). The mixture was brought to the boil. 
Refluxing was continued for an hour. Heating was stopped and the mixture allowed to cool and 
stand overnight. The solvent was evaporated. The resulting tan mass was washed with portions 
of ether (3 x 10 mL) and dried.  
Yield: 0.59 g (88%),  mp 167-168 °C 
FT-IR: nmax  3313, 3279, 3120, 2954, 2935, 2871, 1686, 1594, 1582, 1526, 1364, 1256, 1184, 
1163, 1115, 920 cm -1 
1H-NMR (DMSO-d6): d  10.41 (s, 1H), 8.03 (d, 2H), 7.85 (d, 2H), 7.46 (s, 1H), 2.51 (s, 6H), 
2.38 (t, 2H), 2.00 (quartet, 2H), 1.59 (quintet, 2H), 1.33 (sextet, 2H), 0.90 (t, 3H), 0.81 (t, 3H)   
13C-NMR (ppm, DMSO-d6):  d  172.71, 172.14, 170.30, 156.04, 144.81, 132.53, 130.50, 121.07, 
118.80, 36.70, 29.32, 27.51, 23.72, 22.23, 14.16, 8.35   
 Anal.  Calcd for C20H26N4O4S:  C, 57.40; H, 6.26; N, 13.39. 
                 Found:  C, 57.56; H, 6.16; N, 13.41. 
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This compound was prepared in a manner similar in procedure and scale to compound XXVIII, 
from the reaction of XV with acetic anhydride.   
Yield: 0.61 g (94%),  mp 220-221 °C 
FT-IR: nmax  3343, 3109, 3068, 1678, 1590, 1526, 1363, 1348, 1315, 1257, 1186, 1161,  
1090 cm -1 
1H-NMR (DMSO-d6): d  10.73 (s, 1H), 8.11-7.55 (m, 9H),  7.48 (s, 1H), 2.56 (s, 6H), 1.83 (s, 
3H)   
13C-NMR (ppm, DMSO-d6):  d  170.35, 168.94, 166.73, 156.31, 144.86, 134.80, 133.10, 132.58, 
130.32, 128.99, 128.35, 121.15, 120.09, 24.30, 23.74    
 Anal.  Calcd for C21H20N4O4S:  C, 59.42; H, 4.75; N, 13.20. 
                 Found:  C, 59.35; H, 4.40; N, 13.10. 
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This compound was prepared in a similar way and on the same scale as compound XXVIII from 
the reaction of compound VIII with butyric anhydride.  
Yield: 0.67 g (96%),  mp 176-177 °C 
FT-IR: nmax  3263, 3190, 3115, 2963, 2873, 1709 (sh), 1674, 1589, 1529, 1363, 1161, 1090 cm -1 
1H-NMR (DMSO-d6): d  10.39 (s, 1H), 8.03 (d, 2H), 7.85 (d, 2H), 7.46 (s, 1H), 2.54 (s, 6H), 
2.38 (t, 2H), 1.96 (t, 2H),  1.59 (quintet, 2H), 1.37-1.31 (overlapping m, 4H),  0.90 (t, 3H), 0.68 
(t, 3H)   
13C-NMR (ppm, DMSO-d6):  d  172.68, 171.31, 170.27, 156.05, 144.80, 132.59, 130.47, 121.07, 
118.76, 37.41, 36.70, 27.50, 23.73, 22.24, 17.41, 14.16, 13.50      
 Anal.  Calcd for C21H28N4O4S:  C, 58.31; H, 6.52; N, 12.95. 
                 Found:  C, 58.20; H, 6.36; N, 12.95. 
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An attempt to prepare this compound was made in a similar way and on the same scale as 
compound XXX from the reaction of compound VIII with iso-butyric anhydride. The reaction 
failed, and the information is included here for the sake of completeness. Following the usual 
procedure, a mixture was obtained, comprised mostly of recovered VIII.  Notably, we observed 
the 1H-NMR signal of VIII near  d 11.8 as still being present. We speculate that the introduction 
of additional substitution at the alpha-position of the anhydride disfavors the reaction, even under 
the fairly vigorous conditions which we used. 
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This compound was prepared in a similar way and on the same scale as compound XIII from the 
reaction of compound VIII with valeric anhydride.  
Yield: 0.50 g (86%),  mp 169-170 °C 
FT-IR: nmax  3262, 3193, 3117, 3058, 2955, 2929, 2871, 1710 (sh), 1674, 1589, 1530, 1364, 
1162, 1091 cm -1 
1H-NMR (DMSO-d6): d  10.39 (s, 1H), 8.03 (d, 2H), 7.86 (d, 2H), 7.46 (s, 1H), 2.54 (s, 6H), 
2.38 (t, 2H), 1.97 (t, 2H),  1.59 (quintet, 2H), 1.32 (overlapping m, 4H),  1.06 (sextet, 2H), 0.90 
(t, 3H), 0.69 (t, 3H)   
13C-NMR (ppm, DMSO-d6):  d  172.68, 171.41, 170.25, 156.08, 144.80, 132.56, 130.46, 121.05, 
118.76, 36.70, 35.27, 27.50, 26.03, 23.72, 22.23, 21.62, 14.16, 13.90       
 Anal.  Calcd for C22H30N4O4S:  C, 59.17; H, 6.77; N, 12.55. 









This compound was prepared in a manner similar in procedure and scale to compound XXVIII, 
from the reaction of XV with propionic anhydride.   
Yield: 0.74 g (97%),  mp 204-205 °C 
FT-IR: nmax  3375, 3110, 3045, 2987, 2038, 2880, 1692 (sh), 1676, 1590, 1522, 1499, 1312, 
1163, 1090, 1074 cm -1 
1H-NMR (DMSO-d6): d  10.75 (s, 1H), 8.12-7.58 (m, 9H),  7.48 (s, 1H), 2.55 (s, 6H), 2.03 
(quartet, 2H), 0.83 (s, 3H)   
13C-NMR (ppm, DMSO-d6):  d  172.18, 170.35, 166.72, 156.03, 144.82, 134.82, 133.21, 132.56, 
130.36, 128.98, 128.36, 121.12, 120.07, 29.35, 23.74, 8.37     
 Anal.  Calcd for C22H22N4O4S:  C, 60.26; H, 5.06; N, 12.78. 








This compound was prepared in a manner similar in procedure and scale to compound XXVIII, 
from the reaction of XV with butyric anhydride.   
Yield: 0.68 g (87%),  mp 204 °C 
FT-IR: nmax  3321, 3112, 3064, 2965,2932, 2873, 1709 (sh), 1656, 1591, 1519, 1164, 1109, 
1089, 832 cm -1 
1H-NMR (DMSO-d6): d  10.73 (s, 1H), 8.12-7.56 (m, 9H),  7.48 (s, 1H), 2.56 (s, 6H), 1.99 (t, 
2H), 1.38 (sextet, 2H), 0.70 (t, 3H). Each of the three high-field multiplets appeared to be the 
very close overlap of two equal-sized signals, possibly indicating hindered rotation.   
13C-NMR (ppm, DMSO-d6):  d  171.36, 170.31, 166.71, 156.05, 144.80, 134.83, 133.31, 132.55, 
130.31, 128.97, 128.35, 121.12, 120.05, 37.43, 23.76, 17.43, 13.53      
 Anal.  Calcd for C23H24N4O4S:  C, 61.05; H, 5.35; N, 12.38. 
                 Found:  C, 61.02; H, 5.40; N, 12.47. 
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An attempt to prepare this compound was made in a similar way and on the same scale as 
compound XXVIII from the reaction of compound XV with valeric anhydride. Although some 
of the characteristics of the compound were suitable for the proposed structure, we believe that 
the compound was air or moisture sensitive. The data are included here for the sake of 
completeness. Following the usual procedure, a beige solid was obtained, much in keeping with 
the expectations of previous examples. The material was easily recrystallized from ethanol, 
initially yielding a white microcrystalline solid. Upon standing in the recrystallization solvent, 
however, the white solid changed into larger brown crystals, which were filtered off and dried. 
Yield: 0.60 g (87%; caveat: based on the assumed structure), mp 182 °C 
FT-IR: nmax  3322, 3062, 2967, 2929, 2903, 2853, 1710 (sh), 1655, 1591, 1518, 1358, 1316, 
1162 cm -1 
1H-NMR (DMSO-d6): Indicative of a mixture   
13C-NMR (ppm, DMSO-d6):  Indicative of a mixture  
Thin-Layer Chromatography (silica gel; ethyl acetate:ether, 1:1): Two spots, Rf 0.55 and Rf 0.70.      
 Anal.  Calcd for C24H26N4O4S . 0.20 H2O:  C, 61.31; H, 5.66; N, 11.92. 





Results and Discussion 
	
In their function as xenobiotic-metabolizing enzymes, arylamine N-acetyltransferases are able to 
acetylate the terminal amine of all common sulfa drugs, producing a metabolite with a 
significantly decreased activity against tuberculosis. Any modification of sulfa drugs should first 
consider strategies to block or avoid this de-activating action by NATs, and will therefore require 
a uniform, reliable, and reproducible protocol to synthesize the sulfa metabolites on gram-scale. 
Since no such protocol was found in the literature, our lab began our exploration into the sulfa 
drugs by testing a number of conditions, arriving at a method with excellent yield and purity. 
 
SULFA METABOLITE PROTOCOL 
	
Our initial protocol to produce the sulfa metabolites attempted the reaction of 10 mmol of our 
chosen sulfa drug in a large excess of neat acetic anhydride, such that the anhydride acted as both 
the solvent and the electrophilic reagent. While this reaction was successful in high yield and 
good purity when performed with sulfacetamide, further reactions with other sulfa drugs under 
the same conditions yielded impure product. Analysis of the NMR spectra of the impure 
substances revealed two distinct acetyl signals, suggesting di-acetylation at both the desired 
arylamine nitrogen (N4) and the nitrogen of the sulfonamide (N1). The latter was an unexpected 
reaction, as we assumed N1 would be significantly less nucleophilic; conjugation draws electron 
density into the electronegative sulfonyl unit and the carbonyl or heterocycle substituent. The 
acetylation of sulfadiazine yielded a product with a broad melting point approximately 100 °C 
below the expected product’s melting point. This could indicate we produced a different product 
entirely or some combination of products; it is also worth noting that the melting point of 
crystalline sulfa compounds can be highly variable due to polymorphisms in crystal structure.48  
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We returned to sulfamethazine to refine conditions and combat di-acetylation, switching 
to pyridine as a solvent. This choice was suggested to us by general literature on acylation 
procedures, as pyridine is well known for its activating effect on anhydrides. The lone pair on 
pyridine’s basic nitrogen interacts with the carbonyl group of the anhydride in solution, 
increasing the carbon's electrophilicity.67 Instead of using excess acetic anhydride, we limited the 
quantity added such that the molar ratio of sulfa:anhydride was 1:1. While this gave a yield of 
96% and NMR spectra which largely suggested a mono-acetylated compound, there were some 
small peaks in the downfield region of the carbon NMR which could represent impurities, the di-
acetylated product or even unreacted starting material. We performed one more near-identical 
reaction with a sulfa:anhydride ratio of 1:1.1 to ensure all starting material was consumed, but 
found similar results and spectra. We did not pursue the characterization of the minor impurities. 
Returning to the literature for guidance, we switched solvents again and performed a 
reaction on sulfamethazine on the same scale in glacial acetic acid. Pyridine can produce a 
number of side products, including acetylated pyridine from its electrophilic aromatic 
substitution and other unsatisfactory results; additionally, its removal from the reaction requires 
thoughtful treatment. In contrast, the by-product from acetic anhydride after the acetyl moiety 
has been transferred is acetic acid, which is easily removed. The switch to acidic conditions also 
strongly favors mono-acetylation at the more nucleophilic N4 atom. As suggested by these 
principles, the reaction with sulfamethazine and acetic anhydride in acetic acid at 85 °C did not 
need to be recrystallized and yielded clean, definitive spectra that implied a pure mono-
acetylated compound with a yield of 83%. The material was fully characterized and the data 
were entirely consistent with the proposed structure. 
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Figure 10. Representative reaction; the acetylation of sulfathiazole to yield its 
metabolite, N4-acetylsulfathiazole (Compound VI). 
 
Experimentation with choice of solvent and several other factors resulted in a clean and 
reliable synthetic protocol in good yield for the acetylation of sulfa drugs to produce their 
corresponding metabolites. Using this established protocol, we prepared a series of seven 
different acetylated sulfa metabolites (Compounds I-VII). The seven sulfa drugs chosen for 
metabolite preparation are easily obtained in good purity from commercial sources and are 
bench-stable, allowing large quantities to be stored for future reaction. They also exhibit the 
varied N1 substituents possible in sulfa drugs. Our selection consisted of (1) sulfanilamide, the 
original sulfa drug discovered and the simplest in structure; (2) sulfabenzamide and (3) 
sulfacetamide, which are both N1-acylated; (4) sulfadiazine, (5) sulfamerazine, (6) 
sulfamethazine, and (7) sulfathiazole, all of which have heterocyclic aromatic rings. The 
similarity between the heterocycles in sulfadiazine, sulfamerazine and sulfamethazine allows 
evaluation of the effect of methyl addition onto the ring, which may have implications for the fit 
of the sulfa drug into the DHPS binding pocket. 
A number of refinements were made to the metabolite protocol as it was applied to the 
rest of the sulfa drugs. We found N1,N4-di-acetylation seemed to occur more frequently when the 
existing N1 substituent was an aromatic heterocycle, e.g. sulfadiazine. We hypothesize that 
electron density is shared more equally across N1 and the heterocycle than it is in the N1 
sulfathiazole





















acetamide compounds. The acetamides are less sensitive to di-acetylation because the 
electrophilic carbon of the carbonyl draws electron density from N1. 
In earlier reactions we added the anhydride portion-wise with a disposable glass pipet. To 
address the more sensitive compounds, we set up an addition funnel with the stopcock adjusted 
so that a single drop of anhydride was added approximately every five seconds. While the 
solvent switch was the major factor in obtaining a clean reaction, implementing a slower addition 
of anhydride to the reaction encouraged mono-acetylation by providing a limited amount of 
electrophile in solution at any given time.  
	When clean samples of our compounds had been prepared in reasonable quantity on 
gram scale, they were shipped to our physician collaborator, Dr. Michael Cynamon, Chief of 
Infectious Diseases at the Syracuse, New York, Veterans Affairs Medical Center. Dr. Cynamon’s 
group performed antibacterial testing in whole-cell assays. Since the compounds prepared in this 
section are chemically identical to the metabolites produced through NAT deactivation of sulfa 
drugs, they are inactive against mycobacteria.   
Figure 11. Structure of metabolites prepared, Compounds I-VII. 





















VALEROYL SERIES AT N4 
Guided by crystallographic images of the pterin-sulfa hybrid in the active site of DHPS, we 
modified the metabolite protocol and began the process of active drug design.36 Our lab's 
previous acylations of isoniazid suggested that acyl chains can lend antitubercular drugs 
interesting antimycobacterial properties.46 Applying the same logic to sulfa drugs, we 
hypothesize that longer acyl substituents at the N4 atom will block de-activation of the drug by 
NATs. In addition, the lipophilicity may lead to more favorable biological properties. 
We made our first foray into novel pharmaceutical space with the synthesis of the 
corresponding valeroyl derivatives of our seven original sulfa drugs (Compounds VIII-XIV). 
These syntheses were again convenient and high-yielding, though the visual appearance of the 
reactions differed slightly from that of the acetylation procedure. Once again, we used a 
symmetric carboxylic anhydride and the corresponding acid: valeric anhydride was added 
dropwise to a slurry of sulfa drug in valeric acid at 80 °C. Although these reactants smelled 
remarkably foul, within two minutes of addition of anhydride the white slurry had cleared to a 
homogeneous yellow solution. The solution also spontaneously heated upon addition of the 
anhydride, reaching 105 °C. After several minutes at this higher temperature, the solution 
became opaque again, eventually returning to a slurry texture. The temperature was maintained 
for an hour. The homogenization of the solution suggests that although the original sulfa drug 
may not have perfect solubility in valeric acid at 85 °C, it was rapidly converted to product. If 
this was indeed the case, solubility was not an issue – the product was obtained as a white solid 
in excellent yield after cooling to room temperature, quenching over chipped ice, and drying. 
Spectral analysis indicated the desired compound was formed. The analytical sample was 
obtained by hot wash recrystallization with ethanol. 
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Figure 12. Representative reaction; reaction of sulfamethazine with 
valeric anhydride to yield its N4-valeroyl derivative (Compound XIII).  
Added N4 valeroyl group shown in blue. 
 
BULKIER N4 ACYLATIONS 
We followed our work with straight-chain acylations by increasing the steric bulk of the N4 
substituents; these compounds furthered our exploration of the lipophilicity and three-
dimensional shape in this area of the DHPS binding pocket. We focused on several promising 
sulfa drugs as our starting materials, mostly sulfamethazine and sulfathiazole. Acyl groups of 
several types were used, including benzoyl rings, long straight-chains, and various sizes of 
saturated carbon rings. A number of compounds were prepared in the pursuit of this objective, 


























Figure 13. “Bulkier” N4-acyl substituents on sulfathiazole and sulfamethazine scaffolds. 
 
Unlike the valeroyl or acetyl reactions, anhydrides of these acyl substituents would be 
difficult to obtain or work with. In addition, using the parent carboxylic acid as solvent was 
generally impractical; for example, the use of benzoic anhydride (a solid) in benzoic acid (a solid 
at room temperature and at 85 °C) was not suitable. For this reason, we turned to more reactive 
electrophiles in the use of the acid chlorides, and switched to pyridine as a solvent. Pyridine is 
hypothesized to form a complex with the electrophilic carbon of the acid chloride’s carbonyl 
group, stabilizing the carbon atom’s partial positive charge with the pyridine nitrogen's lone pair 
and increasing overall reactivity of the electrophile.67 
While the acid chloride/pyridine reactions are not as convenient as the anhydride/acid 
reactions, they have the benefit of easily dissolving the reactants. Solutions were homogenous 






















still observed upon the addition of the anhydride, and quenching over ice yielded voluminous 
white precipitate, often immediately. With solubility definitively eliminated as a concern and 
continuing high yields, we were able to obtain pure samples for biological analysis through a 
number of purification procedures, used as needed. 
Among these techniques was trituration with ether, a process designed to remove 
impurities from a solid through careful choice of solvents. The solid is ground into a suspension 
in the solvent; impurities dissolve into the ether, which is then filtered off.68 For some 
compounds, we washed the material with hot ethanol. Other compounds were purified by the 
classic technique of recrystallization from ethanol. Occasionally, we dried our analytical samples 
in a dessicator under house vacuum (350 torr). The Experimental section contains a detailed 
account of which techniques were applied to each compound. 
 
SELECTIVE DIACYLATION 
Our laboratory’s progression from metabolite protocol to valeroyl series to bulkier acylations 
allowed us to make meaningful deductions about the sensitivity of the DHPS binding pocket and 
its relationship to anti-tubercular activity, as discussed further below. We next addressed a 
related question that had already surfaced during the preparation of previous compounds: the 
relative nucleophilicities of the two nitrogen atoms in sulfa drugs' common scaffold. We knew 
from our initial experiments in metabolite preparation that when an excess of acetic anhydride 
was present, spectral analysis indicated the presence of the di-acetylated compound as a 
significant impurity. While acetylation at N4 is still preferred and occurs first, this result suggests 
that subsequent acetylation at N1 is preferred over a second acetylation at N4. This pattern was 
observed in several different sulfa drugs. In order to gather more information about the relative 
reactivity of these amines, we performed a series of experiments to selectively di-acylate 
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compounds that had already been acylated at N4. The products also provided insight into the role 
of N1 in anti-tubercular activity. 
  The reactants for this group of N1 acylations were the characterized and isolated products 
of previous N4 acylation reactions in our laboratory. A representative example is shown below, 
where N4-valeroylsulfamethazine (Compound VIII) is reacted with acetic anhydride in pyridine 
to produce N1-acetyl-N4-valeroylsulfamethazine (Compound XXVII). Nine compounds were 
prepared in this fashion (Compounds XXVII-XXXV), and two additional compounds were 
intentionally di-acetylated using the excess anhydride method discovered during metabolite 
preparation (Compounds XXV and XXVI). The former compound, di-acetylated sulfanilamide 
(Compound XXV) is chemically identical to the N4 metabolite of sulfacetamide (Compound II) 
and should appear as so in spectral analysis. This was indeed confirmed to be the case. 
Figure 14. Representative reaction; N1 acetylation of N4-valeroylsulfamethazine 
to produce N1-acetyl-N4-valeroylsulfamethazine (Compound XXVII). Added 
N1 acetyl group shown in blue. 
 
To enable direct comparison among biological results, the same sulfa scaffold was used 






















selected sulfamethazine, suggested by a 1947 study of acetylating enzymes by Hans Krebs. 
Krebs found that sulfamethazine responded differently than other sulfa drugs, hinting that it 
might produce the most biochemically active compounds.69 While this did not turn out to be the 
case, our consistency nevertheless equipped us to comment on the relative merits of different 
acyl chains. 
The distribution of the electron density in the environment surrounding N1 decreases its 
nucleophilicity in comparison to N4. Although N4 is an aniline nitrogen with some electron 
density drawn into the adjacent aromatic ring, N1 has two substituents stripping electron density: 
the electronegative sulfur of the sulfonyl group and the aromatic diazine ring. In other sulfa 
drugs, this is still often a heterocycle, acyl or other electron-withdrawing substituent. Earlier 
experiments demonstrated the variable reactivity of N1, such that a shift to an acidic solvent 
prevented the addition of acyl substituents at N1. With this in mind, we performed our sequential 
acylation reactions in pyridine, both to actuate the desired N1 reaction site and to benefit from 
pyridine’s activating effect on anhydrides. 
As expected, the second acylation was more difficult than the first. More vigorous 
conditions were required to obtain the product, i.e. the N1,N4-di-acylated sulfamethazine. In 
addition to the use of pyridine for its activating effect, the electrophile was added in at least five-
fold molar excess. N4-Valeroylsulfamethazine (Compound VIII) and N4-benzoylsulfamethazine 
(Compound XV) were selected as starting materials. Both compounds were reacted with acetic 
through valeric anhydride to add acyl chains from two to five carbon atoms in length. All 
compounds in both series were successfully prepared, isolated, characterized, and shipped to our 
physician collaborators for biological testing. 
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As interesting as the successful preparations are those that were more difficult or even 
failed entirely. An attempt was made to prepare N1-isobutyryl-N4-valeroylsulfamethazine 
(Compound XXXI) using isobutyric anhydride and similar conditions to the other di-acylated 
compounds. Even under these fairly vigorous conditions, a mixture was obtained, comprised 
mostly of starting material. This acyl group is similar to propionyl and butyryl, both of which 
were successfully prepared; we hypothesize the steric bulk of its branched chain interfered with 
its ability interact with N1, which is already sterically hindered from the sulfonyl and methazine 
groups adjacent to it. The alpha carbon of this acyl electrophile is substituted, i.e. a tertiary 
carbon, unlike the other electrophiles used. 
The N1-acyl-N4-benzoyl series, formed by performing successively longer acylations at 
N1 on Compound XV, produced some unique results as the acyl substituent increased in length. 
While two-carbon and three-carbon acylation proceeded as expected (Compounds XXIX and 
XXXIII), N1-butyryl-N4-benzoylsulfamethazine (Compound XXIV) showed unexpected details 
in its H-NMR spectrum. Each of the three high-field multiplets associated with the aliphatic 
chain of the butyryl substituent appeared as two nearly identical sets of peaks, slightly offset 
from one another. The low-field signals and the methyl signal of the methazine were unaffected 
and appeared as predicted, implying that this abnormality was caused by a segment of an 
individual compound, not the presence of starting material or other impurity. The splitting 
pattern suggests restricted rotation of the hydrogens in the N1-acyl chain, which increased our 
curiosity about the steric environment around N1. 
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Figure 15. Close-up view of high-field signals in the H-NMR spectrum of Compound XXIV. 
 
Intrigued by the difficulties encountered in Compound XXIV’s preparation, we attempted 
to increase the length of the N1 acyl chain. The reaction of Compound XV with valeric anhydride 
did not proceed to completion; spectral analysis revealed a mix of starting material and 
valeroylated product. We attempted recrystallization with ethanol, which initially yielded a white 
solid. However, after standing in ethanol, the white crystals merged into larger beige crystals. 
This transformation, as well as the difficulty separating the mixture, suggests the compound 
produced was air- or water-sensitive. Indeed, when the sample was sent for elemental analysis, 
the data were consistent with a hydrate. When recrystallization and trituration failed to separate 
the compounds, a variety of thin layer chromatography (TLC) conditions were tested to 
determine if thick-layer chromatography could be employed. In the end, TLC on silica gel (ethyl 
acetate:ether, 1:1) produced the best separation. Two spots were observed with Rf values of 0.55 
and 0.70, but these were judged to be too close for a thick-layer plate. In the end, the compound 
was deemed as intractable, but the experience of this reaction indicated to us that it was quite 
different from those with shorter N1 chain lengths.  
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The NMR details observed with N1-butyryl-N4-benzoylsulfamethazine and the difficulty 
of the N1-valeroyl reaction indicate N1 acylation becomes less favorable as the length of the 
attempted N1 chain increases. These issues were prominent in the N4-benzoyl series, so we 
reasonably assume that the N4 substituent plays a role in the reactivity of N1. Electron-
withdrawing inductive effects seem unlikely – though the benzoyl substituent is aromatic, it is 
approximately seven atoms away from N1. All reactions in this series were performed in pyridine 
and so were homogeneous and transparent at reaction temperature. Quenching with water was 
necessary to obtain solid product precipitate, demonstrating solubility was not an issue, nor did 
the visual appearance of these two reactions differ significantly from the rest of the series. We 
return, then, to the crystal structures discussed in the background section of this paper. 
Regardless of environment, sulfa drugs are observed to take on the “hinged” conformation 
described earlier.36,43 This sharp bend at the sulfonyl occurs in an otherwise long and relatively 
planar molecule. Though the benzoyl substituent is also two-dimensional, it nevertheless fills 
more space sterically than a flexible straight-chain acyl group like valeroyl. We propose the N4-
benzoyl substituent contributes to steric hindrance at N1, blocking access to N1 by the acyl 
electrophile. 
Taking a first glance at the molecule drawn on paper, the idea may seem counterintuitive. 
To begin with, most carbon-skeleton structures of the sulfa drugs draw the sulfonyl group as 
linear, when of course it is acting as the tetrahedral hinge.  Most of the rest of the molecule is 
conjugated, with the lone pairs of both nitrogen atoms participating in the pi delocalization 
throughout the two aromatic rings and beyond. N4-Benzoyl further contributes to this 
conjugation, with its sp2-hybridized carbon and phenyl ring. Figure 16 offers an energy-
minimized model for the three-dimensional model of the molecule in space. However, note that 
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during an N1 acylation, the nitrogen's lone pair must twist out of conjugation to be free for bond 
formation. This hints at the possibility of a higher energy conformation which is the reactive 
form, where the various chemical moieties may not be as linearly aligned as in the conformation 
expected to predominate. That is, the stablest conformation may not be the reactive 
conformation. We can imagine a situation where the benzoyl group, though many atoms apart 
from N1, might curl under the main body of the sulfa drug in a lobster-tail-like fashion and block 
access to N1 (Fig. 16). N1 is already heavily hindered by the methazine ring and the sulfonyl 
group. This appears to be the most plausible explanation for the phenomenon which was 
observed empirically and therefore requires justification. 
 
Figure 16. Left: Space-filling, energy-minimized structure of N1-isobutyryl-N4-
benzoylsulfamethazine. Right: image of a lobster with its tail curled under its body.70 
 
 
We further note that similar results were obtained when we attempted to acetylate N1 of 
N4-4-phenylbenzoylsulfamethazine (Compound XVI). Again, the reactant (Compound XVI) had 
been fully characterized without complication, but the putative product was intractable. These 
results seem to align with the above observations, reinforcing the hypothesis that steric bulk at 
N4 affects ease of acylation at N1.  
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BIOLOGICAL ASSAY RESULTS 
	
These experiments are useful from an organic chemistry perspective because they expand our 
knowledge about the chemical properties of sulfa drugs and synthesis of their derivatives. With 
these data, our laboratory and others can continue optimization of pharmacokinetic properties, 
fine-tune the fit into the binding pocket, and increase antibacterial effect against tuberculosis. 
Our compounds were tested in whole-cell assays against BCG and the virulent strain M. 
tuberculosis Erdman; the results lay the foundation for more extensive testing, including toxicity 
studies and assays in animal models. We can draw several reasonable conclusions about the 
relative merits of our sulfa drug modifications. 
 The N4-acetyl compounds, or sulfa drug metabolites, are inactive against M. tuberculosis 
as expected. 
We were heartened to discover, thanks to Dr. Cynamon's efforts in biological testing, that 
several of our new compounds were significantly active against tuberculosis. The valeroyl 
derivatives of sulfathiazole (XI) and of sulfacetamide (Compound XII) had MIC values of 16 
µg/mL against TB Erdman, and both cleared the plate of bacterial growth in the BCG tests. 
These compounds are significantly more active than their parent drugs. 
Many of the functionalized sulfa drugs prepared in these experiments were derivatives of 
sulfamethazine. Given our first intuition about the early information supplied by Krebs, this was 
a reasonable approach to our work, while we waited for biological data to shape our further 
efforts. Nonetheless, out of the seven different ring substituents tested, sulfathiazole derivatives 
are in fact more effective against tuberculosis than the sulfamethazine compounds. For example, 
N4-valeroylsulfamethazine (Compound XIII) has MIC values of 64, 64 µg/mL against MTB; the 
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corresponding sulfathiazole derivative, N4-valeroylsulfathiazole (Compound XI) has MIC values 
of 32, 16 µg/mL against MTB. 
The reason for this is not immediately obvious – Lee’s crystallographic image of the 
DHPS binding pocket places the heterocycle close to the solvent front, extending slightly from 
the binding pocket and far from the likely locus of chemical activity. This protrusion is due to the 
minor structural inconsistency between sulfa drugs and the para-aminobenzoic acid molecules 
for which they act as isosteres. It is certainly reasonable, however, to suggest that the unique 
chemical structure of each ring might affect the positioning of the sulfa drug at this point, and so 
shift its conformation in the rest of the pocket as a result. Recall that sulfathiazole is 
characterized by a five-membered heterocycle containing sulfur and nitrogen, while 
sulfamethazine has a six-membered heterocycle containing only nitrogen, with two bulky methyl 
substituents extending at positions meta to its connection to the rest of the sulfa drug. 
The impact of methyl substituents can be specifically examined by comparing the 
structure-activity relationship of corresponding sulfamethazine, sulfamerazine and sulfadiazine 
derivatives. For example, the N4-valeroyl compounds of these three sulfa drugs were tested 
against MTB and displayed varying activities, shown in the table below. Compound VIII was the 
most active and Compound X was the least active, demonstrating the importance of the methyl 
substituents. More detailed SAR would need to performed to determine if this effect is due to fit 
within the binding pocket, lipophilic interactions, permeability, or another cause. 
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R= Compound # Activity in MTB (µg/mL) 
 
 
VIII 64, 64 
 
IX 128, 128 
 
 X 256, 256 
 
Figure 17. Left: Table of activities of sulfamerazine derivative and related compounds. 
Right: Chemical structure of N4-valeroyl derivatives shown in table.  
 
Perhaps the most striking result from biological testing of these compounds is the 
increased activity of longer acyl chains at N4. Although N4 acetylation produces the sulfa 
metabolites, which are significantly less active than their parent drugs, five of the seven N4-
valeroyl compounds demonstrated improvement in activity over their parent drugs. This cannot 
unequivocally confirm a hypothesis, but it certainly aligns with our guiding principles that longer 
acylations might be (1) improving affinity for the binding pocket and (2) preventing de-
activation by NAT enzymes. Another possible, associated benefit is that the increased 
lipophilicity could improve permeability and thus bioavailability. 
Lastly, we investigated acylating both N1 and N4 of sulfa drugs with substituents of 














when compared to their parent sulfa drugs. Since several of the N4-acylated compounds were 
more active than their parents, this suggests that N1 acylation significantly impairs anti-
tubercular action. N1 is therefore still important to activity despite not being directly implicated 
in the sulfa drug/DHPS mechanism of action. This decrease contributes to the evidence that sulfa 
drugs fit into the DHPS binding pocket very precisely, and even a short carbon chain at N1 can 
sufficiently ruin their three-dimensional shape such that they can no longer mimic pABA. This 
decrease in activity provides further information about drug-bacillus interaction. Thus our series 
acted as a chemical probe into the importance of N1 in relation to N4, which is valuable 





Medical science has made enormous strides in the last few centuries. Thanks to the pioneering 
work of scientists such as Gerhard Domagk and Alexander Fleming, we possess chemical 
compounds that can vanquish diseases once thought to be death sentences. Many of the plagues 
of the past have been reduced to footnotes in history: polio, smallpox, and even the Black Plague 
that obliterated enormous swathes of the population in Europe in the fourteenth century. 
Tuberculosis has never been relegated to the background in the same way. It possesses several 
unique qualities that make it difficult to prevent or treat: among them, its thick and waxy cell 
wall and its stasis period lurking inside the body, protected from the immune system. With no 
reliable vaccine and drug resistance rampant in the population, the need for novel antitubercular 
chemotherapy agents is clear. 
Though sulfa drugs have been well-known for over eighty years now, their application to 
treat tuberculosis is a surprisingly unaddressed area of research. Fortunately, in 2007 a medical 
anomaly prompted Pierre Forgacs and his research team to scrutinize the long-held assumption 
that sulfa drugs were not effective against tuberculosis. With a wealth of modern technology at 
our disposal, the scientific community has been able to elucidate sulfa drugs' mechanism of 
action, which stems at least in part from its inhibition of dihydropteroate synthase. We also have 
a deeper understanding of its metabolism by N-acetyltransferases. Previous studies in the Hearn 
lab have enumerated the merits of acylation of antitubercular drugs to avoid de-activation by 
NATs and improve biological properties such as permeability. This thesis presents the results of 
applying that strategy of acylation to a collection of pre-existing sulfa drugs.  
We have developed a reliable, high-yield synthetic protocol for a series of acetylated 
sulfa drugs to enable further study of the NAT metabolites and their properties. One 
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complication during this process was the tendency for a second acetylation to occur at the N1 
atom, which was addressed with careful control of variables such as rate of addition, temperature 
and stoichiometry. As expected, the sulfa NAT metabolites were lower in activity than their 
parent drugs, and we ascertained conditions that provided easy separation and high yield. 
With this foundation, we probed the fit of sulfa drugs into the binding pocket of DHPS 
and NATs by experimenting with increasing acyl chain length at N4. We explored a number of 
different procedures for N4 acylation, focusing on derivatives of sulfamethazine. After we had 
successfully prepared a rich variety of N4-acylated sulfa drugs, we continued to selective di-
acylation at both N4 and N1, varying both chain length and steric bulk. We were hopeful that di-
acyl compounds might fit differently into the active site and show different biological activities. 
These reactions were easily accomplished with click chemistry, and furnished data with 
fascinating implications for the relative nucleophilicities of the two amines. 
The results of whole-cell assays against BCG, TB Erdman, and others suggest the following 
themes for our compounds: 
1. Sulfathiazole derivatives seem to produce the most biologically active compounds out of 
the sulfa drugs surveyed. 
2. While the N4-acetylated derivatives produced by NAT de-activation are inactive against 
tuberculosis, acylation at N4 with longer groups such as valeroyl does produce active 
compounds. This may be due to such compounds' escaping the deactivating action of 
NAT, to a better fit within the pABA binding pocket of DHPS, to better penetration of 
the drug due to enhanced lipophilicity, or perhaps all three. 
3. Acylation at N1 leads to lower activity or even to no activity at all.  
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4. Differences in activity among the sulfamethazine derivatives prepared suggest the factors 
governing results are in delicate balance. 
 
FUTURE DIRECTIONS 
As indicated above, our lab continues to utilize the ongoing biological feedback on our 
compounds, which includes the preparation of sulfathiazole derivatives. We were able to draw a 
number of conclusions based on sulfamethazine which hopefully apply broadly enough to guide 
research with the other sulfa derivatives as well – for example, the deactivation noted after N1 
acylation is dramatic enough to bespeak an effect throughout the entire binding pocket. 
However, in the pursuit of promising compounds for further development, we will seek to 
maximize efficacy by selecting the optimal sulfa framework. 
This is an exciting area of research limited only by one's imagination and the variety of 
sulfa drugs and electrophiles available. While this thesis concerned acyl substitutions, it is easy 
to envision exploring the surrounding chemical space with more diverse electrophiles. Our 
laboratory has already initiated research into N4 Schiff bases of sulfa drugs, which involve 
reaction with an aldehyde and therefore involve very similar chemistry. This is another avenue 
pursued by our lab previously with other anti-tubercular drugs to some success.50 
We eagerly await the biological results from the remaining compounds that were shipped 
to our physician collaborators. The current literature is somewhat ambiguous about the role of 
trimethoprim in augmenting sulfa drugs' activity; evaluating how our compounds act against 
tuberculosis in the presence of trimethoprim versus on their own would certainly be useful 
information to bring to the debate. A sample of our compounds have been tested against 
infectious organisms other than tuberculosis, including S. aureus, E. coli, C. albicans and others. 
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Any hits could lead to an entirely new avenue of drug discovery. Lastly, promising compounds 
from our research would benefit from in vivo studies in mice. 
It would be illuminating to understand the three-dimensional positioning of the reactants 
in our intriguing N1 acylation. X-ray crystallography could capture the shape of N4-
benzoylsulfamethazine and provide insight into the steric factors at play as the electrophile 
approaches N1. Another possibility would be computational modeling of the reactive 
conformation and/or transition state involved in the acylation of N1. Such a study could illustrate 
the orientation of the lone pair on N1, the steric environment around N1, and the source of the 
interaction with the N4 acyl group. We would then be able to confirm or deny our hypothesis, 
and propose an explanation for a phenomenon which so far has only been directly observed at 
the macro level. 
Lastly, we have justified our observations about the biological activity of our compounds 
with the best data available to us: the Lee group's crystallographic snapshot of sulfa drugs 
binding in the DHPS active site. In order to rationalize how the binding pocket is affected by our 
new sulfa compounds, it would be useful to perform docking studies, and our lab has a future 
external collaboration in mind for this. This could point to the reason activity is so sensitive to N1 
acylation, and perhaps fill in some of the details about the mechanism of action of our successful 
compounds. For example, is our molecule still conjugating with DHPP the way 
sulfamethoxazole is illustrated to in the Lee paper? Or is the lipophilic acyl chain interacting 
with the DHPS active site in its own unique way? Understanding the mechanism better would 
guide us in future modifications, allowing us to make reasoned decisions to maximize the 
beneficial interactions. 
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 The threat drug-resistant tuberculosis poses to the global community is undeniable. 
Though this frightening disease has been menacing humanity for many centuries, the scientific 
disciplines have made extraordinary discoveries to combat it in return. This small slice of 






(1)  Signs & Symptoms | Basic TB Facts | TB | CDC 
https://www.cdc.gov/tb/topic/basics/signsandsymptoms.htm (accessed Feb 3, 2019). 
(2)  Daniel, T. M. The History of Tuberculosis. Respir. Med. 2006, 100 (11), 1862–1870. 
https://doi.org/10.1016/j.rmed.2006.08.006. 
(3)  Dubos, R. J.; Dubos, J. The White Plague: Tuberculosis, Man, and Society; Rutgers 
University Press: New Brunswick, 1987. 
(4)  Summers, B. The Deaths of the Bronte Family. Sheppard’s Confidential. December 30, 
2009. 
(5)  Get, R. L. Isolation, Collapsing Lungs and Spitting Bans: Three Ways We Used to Treat 
TB, and Still Might. The Conversation. 
(6)  Herer, B. Tuberculosis and Opera. 2019. 
(7)  Morens, D. M. At the Deathbed of Consumptive Art - Volume 8, Number 11—November 
2002 - Emerging Infectious Diseases Journal - CDC. 
https://doi.org/10.3201/eid0811.020549. 
(8)  Blevins, S. M.; Bronze, M. S. Robert Koch and the ‘Golden Age’ of Bacteriology. Int. J. 
Infect. Dis. 2010, 14 (9), e744–e751. https://doi.org/10.1016/j.ijid.2009.12.003. 
(9)  Koch, R. The Aetiology of Tuberculosis a Translation from the German of the Original 
Paper Announcing the Discovery of the Tubercle Bacillus, Read before the Physiological 
Society in Berlin, March 24, 1882, and Published in the Berliner Klinische Wochenschrift, 
1882, Xix, 221 /; National Tuberculosis Association,: New York :, 1932. 
(10)  Barberis, I.; Bragazzi, N. L.; Galluzzo, L.; Martini, M. The History of Tuberculosis: From 
the First Historical Records to the Isolation of Koch’s Bacillus. J. Prev. Med. Hyg. 2017, 
58 (1), E9–E12. 
(11)  Haygood, T. M. Chest Screening and Tuberculosis in the United States. RadioGraphics 
1994, 14 (5), 1151–1166. https://doi.org/10.1148/radiographics.14.5.7991823. 
(12)  Heemskerk, D.; Caws, M.; Marais, B.; Farrar, J. Tuberculosis in Adults and Children; 
SpringerBriefs in Public Health; Springer International Publishing: Cham, 2015; Vol. 2. 
https://doi.org/10.1007/978-3-319-19132-4. 
(13)  Fogel, N. Tuberculosis: A Disease without Boundaries. Tuberculosis 2015, 95 (5), 527–
531. https://doi.org/10.1016/j.tube.2015.05.017. 
(14)  Hunter, R. L. Tuberculosis as a Three-Act Play: A New Paradigm for the Pathogenesis of 
Pulmonary Tuberculosis. Tuberc. Edinb. Scotl. 2016, 97, 8–17. 
https://doi.org/10.1016/j.tube.2015.11.010. 
	 104 
(15)  Gordon, S. V.; Parish, T. Microbe Profile: Mycobacterium Tuberculosis: Humanity’s 
Deadly Microbial Foe. Microbiology 2018, 164 (4), 437–439. 
https://doi.org/10.1099/mic.0.000601. 
(16)  Kerantzas, C. A.; Jacobs, W. R. Origins of Combination Therapy for Tuberculosis: 
Lessons for Future Antimicrobial Development and Application. mBio 2017, 8 (2). 
https://doi.org/10.1128/mBio.01586-16. 
(17)  Murray, J. F.; Schraufnagel, D. E.; Hopewell, P. C. Treatment of Tuberculosis. A 
Historical Perspective. Ann. Am. Thorac. Soc. 2015, 12 (12), 1749–1759. 
https://doi.org/10.1513/AnnalsATS.201509-632PS. 
(18)  Chakraborty, S.; Rhee, K. Y. Tuberculosis Drug Development: History and Evolution of 
the Mechanism-Based Paradigm. Cold Spring Harb. Perspect. Med. 2015, 5 (8), a021147. 
https://doi.org/10.1101/cshperspect.a021147. 
(19)  Sepkowitz, K. A.; Raffalli, J.; Riley, L.; Kiehn, T. E.; Armstrong, D. Tuberculosis in the 
AIDS Era. Clin. Microbiol. Rev. 1995, 8 (2), 180–199. 
https://doi.org/10.1128/CMR.8.2.180. 
(20)  World Health Organization. Global Tuberculosis Report 2018; 2018. 
(21)  Treatment for TB Disease | Treatment | TB | CDC 
https://www.cdc.gov/tb/topic/treatment/tbdisease.htm (accessed Sep 27, 2018). 
(22)  Horsburgh, C. R.; Barry, C. E.; Lange, C. Treatment of Tuberculosis. N. Engl. J. Med. 
2015, 373 (22), 2149–2160. https://doi.org/10.1056/NEJMra1413919. 
(23)  Matsumoto, T.; Ohno, M.; Azuma, J. Future of Pharmacogenetics-Based Therapy for 
Tuberculosis. Pharmacogenomics Lond. 2014, 15 (5), 601–607. 
http://dx.doi.org.ezproxy.wellesley.edu/10.2217/pgs.14.38. 
(24)  Bentley, R. Different Roads to Discovery; Prontosil (Hence Sulfa Drugs) and Penicillin 
(Hence β-Lactams). J. Ind. Microbiol. Biotechnol. 2009, 36 (6), 775–786. 
https://doi.org/10.1007/s10295-009-0553-8. 
(25)  Otten, H. Domagk and the Development of the Sulphonamides. J. Antimicrob. Chemother. 
1986, 17 (6), 689–690. https://doi.org/10.1093/jac/17.6.689. 
(26)  Stork, W. Top Pharmaceuticals: Prontosil. Chemical & Engineering News. June 20, 2005. 
(27)  Jayachandran, S.; Lleras-Muney, A.; Smith, K. V. Modern Medicine and the Twentieth 
Century Decline in Mortality: Evidence on the Impact of Sulfa Drugs. Am. Econ. J. Appl. 
Econ. 2010, 2 (2), 118–146. https://doi.org/10.1257/app.2.2.118. 
(28)  Cohen, L. S.; Cluff, L. E. The Sulfonamides. Am. J. Nurs. 1961, 61 (6), 54–58. 
https://doi.org/10.2307/3451714. 
	 105 
(29)  Forgacs, P.; Wengenack, N. L.; Hall, L.; Zimmerman, S. K.; Silverman, M. L.; Roberts, G. 
D. Tuberculosis and Trimethoprim-Sulfamethoxazole. Antimicrob. Agents Chemother. 
2009, 53 (11), 4789–4793. https://doi.org/10.1128/AAC.01658-08. 
(30)  Ong, W.; Sievers, A.; Leslie, D. E. Mycobacterium Tuberculosis and Sulfamethoxazole 
Susceptibility. Antimicrob. Agents Chemother. 2010, 54 (6), 2748–2749. 
https://doi.org/10.1128/AAC.00029-10. 
(31)  Richard J. Wallace, Jr.; Wiss, K.; Bushby, M. B.; Hollowell, D. C. In Vitro Activity of 
Trimethoprim and Sulfamethoxazole against the Nontuberculous Mycobacteria. Rev. 
Infect. Dis. 1982, 4 (2), 326–331. 
(32)  Davies Forsman, L.; Schön, T.; Simonsson, U. S. H.; Bruchfeld, J.; Larsson, M.; Juréen, 
P.; Sturegård, E.; Giske, C. G.; Ängeby, K. Intra- and Extracellular Activities of 
Trimethoprim-Sulfamethoxazole against Susceptible and Multidrug-Resistant 
Mycobacterium Tuberculosis. Antimicrob. Agents Chemother. 2014, 58 (12), 7557–7559. 
https://doi.org/10.1128/AAC.02995-14. 
(33)  Raoult, D. Old Antibiotics for Tuberculosis. Clin. Infect. Dis. 2017, 64 (7), 983–983. 
https://doi.org/10.1093/cid/cix037. 
(34)  Seddon, J. A.; Makhene, M. K.; Gumbo, T. Reply to Raoult. Clin. Infect. Dis. 2017, 64 
(7), 984–984. https://doi.org/10.1093/cid/cix038. 
(35)  Bermingham, A.; Derrick, J. P. The Folic Acid Biosynthesis Pathway in Bacteria: 
Evaluation of Potential for Antibacterial Drug Discovery. BioEssays 2002, 24 (7), 637–
648. https://doi.org/10.1002/bies.10114. 
(36)  Yun, M.-K.; Wu, Y.; Li, Z.; Zhao, Y.; Waddell, M. B.; Ferreira, A. M.; Lee, R. E.; 
Bashford, D.; White, S. W. Catalysis and Sulfa Drug Resistance in Dihydropteroate 
Synthase. Science 2012, 335 (6072), 1110–1114. https://doi.org/10.1126/science.1214641. 
(37)  Hammoudeh, D. I.; Zhao, Y.; White, S. W.; Lee, R. E. Replacing Sulfa Drugs with Novel 
DHPS Inhibitors. Future Med. Chem. 2013, 5 (11), 1331–1340. 
https://doi.org/10.4155/fmc.13.97. 
(38)  Zhao, Y.; Shadrick, W. R.; Wallace, M. J.; Wu, Y.; Griffith, E. C.; Qi, J.; Yun, M.-K.; 
White, S. W.; Lee, R. E. Pterin-Sulfa Conjugates as Dihydropteroate Synthase Inhibitors 
and Antibacterial Agents. Bioorg. Med. Chem. Lett. 2016, 26 (16), 3950–3954. 
https://doi.org/10.1016/j.bmcl.2016.07.006. 
(39)  Upton, A.; Johnson, N.; Sandy, J.; Sim, E. Arylamine N-Acetyltransferases – of Mice, 
Men and Microorganisms. Trends Pharmacol. Sci. 2001, 22 (3), 140–146. 
https://doi.org/10.1016/S0165-6147(00)01639-4. 
(40)  Sim, E.; Lack, N.; Wang, C.-J.; Long, H.; Westwood, I.; Fullam, E.; Kawamura, A. 
Arylamine N-Acetyltransferases: Structural and Functional Implications of 
	 106 
Polymorphisms. Toxicology 2008, 254 (3), 170–183. 
https://doi.org/10.1016/j.tox.2008.08.022. 
(41)  Abuhammad, A.; Fullam, E.; Bhakta, S.; Russell, A.; Morris, G.; Finn, P.; Sim, E. 
Exploration of Piperidinols as Potential Antitubercular Agents. Molecules 2014, 19 (10), 
16274–16290. https://doi.org/10.3390/molecules191016274. 
(42)  Sikora, A. L.; Frankel, B. A.; Blanchard, J. S. Kinetic and Chemical Mechanism of 
Arylamine N-Acetyltransferase from Mycobacterium Tuberculosis. Biochemistry 2008, 47 
(40), 10781–10789. https://doi.org/10.1021/bi800398c. 
(43)  Wu, H.; Dombrovsky, L.; Tempel, W.; Martin, F.; Loppnau, P.; Goodfellow, G. H.; Grant, 
D. M.; Plotnikov, A. N. Structural Basis of Substrate-Binding Specificity of Human 
Arylamine N-Acetyltransferases. J. Biol. Chem. 2007, 282 (41), 30189–30197. 
https://doi.org/10.1074/jbc.M704138200. 
(44)  Laurieri, N.; Dairou, J.; Egleton, J. E.; Stanley, L. A.; Russell, A. J.; Dupret, J.-M.; Sim, 
E.; Rodrigues-Lima, F. From Arylamine N-Acetyltransferase to Folate-Dependent Acetyl 
CoA Hydrolase: Impact of Folic Acid on the Activity of (HUMAN)NAT1 and Its 
Homologue (MOUSE)NAT2. PLoS ONE 2014, 9 (5), e96370. 
https://doi.org/10.1371/journal.pone.0096370. 
(45)  McDonagh, E. M.; Boukouvala, S.; Aklillu, E.; Hein, D. W.; Altman, R. B.; Klein, T. E. 
PharmGKB Summary: Very Important Pharmacogene Information for N-
Acetyltransferase 2. Pharmacogenet. Genomics 2014, 24 (8), 409–425. 
https://doi.org/10.1097/FPC.0000000000000062. 
(46)  Hearn, M. J.; Cynamon, M. H. In Vitro and In Vivo Activities of Acylated Derivatives of 
Isoniazid Against Mycobacterium Tuberculosis. Drug Des. Discov. 2003, 18 (4), 103–108. 
(47)  Winiwarter, S.; Ridderström, M.; Ungell, A.-L.; Andersson, T. B.; Zamora, I. 5.22 - Use 
of Molecular Descriptors for Absorption, Distribution, Metabolism, and Excretion 
Predictions. In Comprehensive Medicinal Chemistry II; Taylor, J. B., Triggle, D. J., Eds.; 
Elsevier: Oxford, 2007; pp 531–554. https://doi.org/10.1016/B0-08-045044-X/00140-1. 
(48)  Castle, R. N.; Witt, N. F. The Polymorphism of Sulfapyridine. J. Am. Chem. Soc. 1946, 68 
(1), 64–66. https://doi.org/10.1021/ja01205a020. 
(49)  Hudzicki, J. Kirby-Bauer Disk Diffusion Susceptibility Test Protocol 
http://www.asmscience.org/content/education/protocol/protocol.3189 (accessed Mar 14, 
2019). 
(50)  Hearn, M. J.; Cynamon, M. H. Design and Synthesis of Antituberculars: Preparation and 
Evaluation against Mycobacterium Tuberculosis of an Isoniazid Schiff Base. J. 
Antimicrob. Chemother. 2004, 53 (2), 185–191. https://doi.org/10.1093/jac/dkh041. 
	 107 
(51)  Vestal, A. L.; Center for Disease Control. Procedures for the Isolation and Identification 
of Mycobacteria; DHEW publication ; no. (CDC) 75-8230; Dept. of Health, Education, 
and Welfare, Public Health Service, Center for Disease Control, Bureau of Laboratories, 
Training and Consultation Division ; for sale by the Supt. of Docs., U.S. Govt. Print. Off.: 
Atlanta, Ga. : Washington, 1977. 
(52)  Wong, C. S.; Palmer, G. S.; Cynamon, M. H. In-Vitro Susceptibility of Mycobacterium 
Tuberculosis, Mycobacterium Bovis and Mycobacterium Kansasii to Amoxycillin and 
Ticarcillin in Combination with Clavulanic Acid. J. Antimicrob. Chemother. 1988, 22 (6), 
863–866. 
(53)  Manabe, Y. C.; Dannenberg, A. M.; Tyagi, S. K.; Hatem, C. L.; Yoder, M.; Woolwine, S. 
C.; Zook, B. C.; Pitt, M. L. M.; Bishai, W. R. Different Strains of Mycobacterium 
Tuberculosis Cause Various Spectrums of Disease in the Rabbit Model of Tuberculosis. 
Infect. Immun. 2003, 71 (10), 6004–6011. https://doi.org/10.1128/IAI.71.10.6004-
6011.2003. 
(54)  Nováček, A. Acylation of Some Urea Derivatives. Collect. Czechoslov. Chem. Commun. 
1967, 32, 1712–1718. https://doi.org/10.1135/cccc19671712. 
(55)  N4-Acetylsulfamethazine | C14H16N4O3S | ChemSpider 
http://www.chemspider.com/Chemical-Structure.60219.html (accessed Mar 3, 2019). 
(56)  Sprague, J. M. 2-(Benzenesulfonamido)-Tetrahydrobenzothiazoles., January 10, 1950. 
(57)  Sprague, J. M. Sulfapyrimidines., September 17, 1946. 
(58)  Tsuda, K.; Sakamoto, Shusaku. Syntheses of Sulfanilamides. V. Disulfanilyl Derivatives 
of 2-Aminothiazole. 2. Yakugaku Zasshi 1949, 69 (Copyright (C) 2019 American 
Chemical Society (ACS). All Rights Reserved.), 165–171. 
https://doi.org/10.1248/yakushi1947.69.4_165. 
(59)  Spectrum ID BR076533 for CAS Registry Number 127-76-4 
https://scifinder.cas.org/scifinder/view/link_v1/substance.html?l=t7c60yhXV6sylF1Mo8l
N1zTBGvNwMg2-aVM20EivtK8U4wCWwdPuw4CWz0MZMJgW. 
(60)  Irani, R. J. A Simple Method of Preparation of N4-Substituted Disulfanilamido 
Derivatives of Some Dibasic Acids. Curr. Sci. 1945, 14 (Copyright (C) 2019 American 
Chemical Society (ACS). All Rights Reserved.), 46–47. 
(61)  Schwarz, R.; Kristen, Ch. Behavior of Sulfonamides on Sterilization in Hot Air. Sci. 
Pharm. 1965, 33 (Copyright (C) 2019 American Chemical Society (ACS). All Rights 
Reserved.), 145–153. 




(63)  Patki, V. M.; Shirsat, M. V. Chemotherapy of Intestinal Infections. I. Synthesis of N4-
Acyl Derivatives of N1-Substituted Sulfanilamides. J. Sci. Ind. Res. 1959, 18C (Copyright 
(C) 2019 American Chemical Society (ACS). All Rights Reserved.), 113–116. 
(64)  Predict 1H NMR spectra 
http://www.cheminfo.org/Spectra/NMR/Predictions/1H_Prediction/index.html (accessed 
Mar 28, 2019). 
(65)  Ueda, T.; Kato, S.; Toyoshima, Shigeru. 2-N1-Acylsulfanilamidothiazole., June 10, 1961. 
(66)  Melegari, M.; Vampa, G.; Benedetti, L.; De Benedetti, P. G. Preparation and 
Spectroscopic Behavior of Acetyl Derivatives of Sulfonamides. Farmaco. [Sci.] 1976, 31 
(Copyright (C) 2019 American Chemical Society (ACS). All Rights Reserved.), 183–193. 
(67)  Greeves, N. Pyridine - Nucleophilic Catalyst http://www.chemtube3d.com/Pyridine%20-
%20Nucleophilic%20Catalyst.html (accessed Apr 18, 2019). 
(68)  Performing a Trituration 
http://www.commonorganicchemistry.com/Sidebar/Trituration.htm (accessed Apr 8, 
2019). 
(69)  Krebs, H. A.; Sykes, W. O.; Bartley, W. C. Acetylation and Deacetylation of the P-Amino 
Group of Sulphonamide Drugs in Animal Tissues. Biochem. J. 1947, 41 (4), 622–630. 
https://doi.org/10.1042/bj0410622. 
(70)  Citron. English: Acanthocaris Tenuimana; 2010. 
 
